Поиск
Закладки
Озвучить текст Озвучить книгу
Изменить режим чтения
Изменить размер шрифта
Оглавление
Для озвучивания и цитирования книги перейдите в режим постраничного просмотра.
Фибрилляция и трепетание предсердий у взрослых

Список литературы

  1. Howick JH. The Philosophy of Evidence-based Medicine. Wiley. p. 15. ISBN 978–1–4443–4266– 6.
  2. Федеральный закон от 21.11.2011 № 323-ФЗ (ред. от 03.04.2017) «Об основах охраны здоровья граждан в Российской Федерации».
  3. Эпидемиологический словарь / под ред. Джона М.Ласта для Международной эпидемиологической ассоциации. – 4-е изд. – Москва, 2009. – 316 с.
  4. Федеральное агентство по техническому регулированию и метрологии. Национальный стандарт Российской Федерации. ГОСТР 52379–2005. Надлежащая клиническая практика. – Москва, 2005.
  5. Федеральный закон от 12.04.2010 № 61-ФЗ (ред. от 03.07.2016) «Об обращении лекарственных средств».
  6. Малая медицинская энциклопедия [Электронный ресурс]. – М.: Медицинская энциклопедия. 1991–96 гг. Режим доступа: http://dic.academic.ru/dic.nsf/enc_medicine/28878/Синдром.
  7. Андреева Н.С., Реброва О.Ю., Зорин Н.А. Системы оценки достоверности научных доказательств и убедительности рекомендаций: сравнительная характеристика и перспективы унификации. // Медицинские технологии. Оценка и выбор. –2012. – № 4. – С. 10–24.
  8. Sanchez PL, Fernandez-Aviles F. Structural heart disease: a new chapter in cardiovascular disease. ESC Monographic issue: Structural Heart Disease. Eur Heart J. 2010;12:e1.
  9. Nieuwlaat R, Capucci A, Camm AJ et al. Atrial fibrillation management: a prospective survey in ESC member countries: the Euro Heart Survey on Atrial Fibrillation. Eur Heart J. 2005;26:2422– 2434.
  10. Nabauer M, Gerth A, Limbourg T et al. The Registry of the German Competence NETwork on Atrial Fibrillation: patient characteristics and initial management. Europace. 2009;11:423–434.
  11. Wong CX, Sullivan T, Sun MT et al. Obesity and the Risk of Incident, Post-Operative, and Post-Ablation Atrial Fibrillation: A Meta-Analysis of 626 603 Individuals in 51 Studies. JACC: clinical electrophysiology. 2015;3:139–152.
  12. Голухова Е.З., Громова О.И., Булаева Н.И. и др. Эпикардиальный жир и фибрилляция предсердий: роль профиброгенных медиаторов. Кардиология. 2018;58:58–64.
  13. Stewart S, Hart CL, Hole DJ, McMurray JJ. Population prevalence, incidence, and predictors of atrial fibrillation in the Renfrew/Paisley study. Heart. 2001;86:516–521.
  14. Go AS, Hylek EM, Phillips KA et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA. 2001;285:2370–2375.
  15. Miyasaka Y, Barnes ME, Gersh BJ et al. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation. 2006;114:119–125.
  16. Heeringa J, van der Kuip DA, Hofman A et al. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. Eur Heart J. 2006;27:949–953.
  17. Naccarelli GV, Varker H, Lin J, Schulman KL. Increasing prevalence of atrial fibrillation and flutter in the United States. Am J Cardiol. 2009;104:1534–1539.
  18. Thrall G, Lane D, Carroll D, Lip GY. Quality of life in patients with atrial fibrillation: a systematic review. Am J Med. 2006;119:448.e1–19.
  19. Dorian P, Jung W, Newman D et al. The impairment of health-related quality of life in patients with intermittent atrial fibrillation: implications for the assessment of investigation altherapy. J Am Coll Cardiol. 2000;36:1303– 1309.
  20. Sears SF, Serber ER, Alvarez LG et al. Understanding atrial symptom reports: objective versus subjective predictors. Pacing Clin Electrophysiol. 2005;28:801–807.
  21. Peinado R, Arribas F, Ormaetxe JM, Badia X. Variation in quality of life with type of atrial fibrillation. Rev Esp Cardiol. 2010;63:1402–1409.
  22. Steg PG, Alam S, Chiang CE et al. Realise AF investigators. Symptoms, functional status and quality of life in patients with controlled and uncontrolled atrial fibrillation: data from the Realise AF cross-sectional international registry. Heart. 2012;98:195–201.
  23. Kirchhof P, Benussi S, Dipak Kotecha et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. European heart journal. 2016:50:e1-e88.
  24. Wynn GJ, Todd DM, Webber M et al. The European Heart Rhythm Association symptom classification for atrial fibrillation: validation and improvement through a simple modification. Europace. 2014;16:965–972.
  25. Kirchhof P, Auricchio A, Bax J et al. Outcome parameters for trials in atrial fibrillation: executive summary. Eur Heart J. 2007;28:2803–2817.
  26. Lowres N, Neubeck L, Redfern et al. Screening to identify unknown atrial fibrillation. A systematic review. Thromb Haemost 2013;110:213–222
  27. Руководство по кардиологии в четырех томах Под редакцией академика Е. И. Чазова. Москва, «Практика», 2014.
  28. Ревишвили А.Ш., Шляхто Е.В., Попов С.В. и др. Российские клинические рекомендации по проведению электрофизиологических исследований, катетерной абляции и применению имплантируемых антиаритмических устройств. – Москва: ВНОА, 2017. – 701 с.
  29. Сулимов В.А., Голицин В.П., Панченко Е.П. и др. Диагностика и лечение фибрилляции предсердий. Рекомендации РКО, ВНОА, АССХ. – Москва, 2013. – 112 с.
  30. Бокерия Л.А., Бокерия О.Л., Голухова Е.З. и др. Клинические рекомендации: «Фибрилляция предсердий». ФГБУ ННПЦССХ им. А.Н. Бакулева» МЗ РФ– Москва, 2017. – 65 с.
  31. Grond M, Jauss M, Hamann G et al. Improved detection of silent atrial fibrillation using 72-hour Holter ECG in patients with ischemic stroke: a prospective multicenter cohort study. Stroke 2013;44:3357–3364
  32. Donal E, Lip GY, Galderisi M et al. EACVI/EHRA Expert Consensus Document on the role of multi-modality imaging for the evaluation of patients with atrial fibrillation. Eur Heart J Cardiovasc Imaging. 2016;17:355–383.
  33. Rizos T, Guntner J, Jenetzky E et al. Continuous stroke unit electrocardiographic monitoring versus 24-hour Holter electrocardiography for detection of paroxysmal atrial fibrillation after stroke. Stroke 2012;43: 2689 – 2694.
  34. Guerra F. et al. Implanted Devices and Atrial Fibrillation //Current Issues and Recent Advances in Pacemaker Therapy. – 2012. – С. 105.
  35. Sanna T, Diener HC, Passman RS et al. CRYSTAL AF Investigators. Cryptogenic stroke and underlying atrial fibrillation. N Engl J Med. 2014;370:2478–2486.
  36. Engdahl J, Andersson L, Mirskaya M, Rosenqvist M. Stepwise screening of atrial fibrillation in a 75-year-old population: implications for stroke prevention. Circulation. 2013;127:930–937.
  37. Svennberg E, Engdahl J, Al-Khalili F et al. Mass Screening for Untreated Atrial Fibrillation: The STROKESTOP Study. Circulation. 2015;131:2176–2184.
  38. Gage BF, Yan Y, Milligan PE et al. Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF). Am Heart J. 2006;151:713–719.
  39. Hijazi Z, Oldgren J, Lindback Jetal ARISTOTLE and RE-LY Investigators. The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study. Lancet. 2016;387:2302–2311.
  40. Connolly SJ, Ezekowitz MD, Yusuf S et al. RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139– 1151.
  41. Granger CB, Alexander JH, McMurray JJ et al. ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981–992.
  42. Patel MR, Mahaffey KW, Garg J et al. ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883–891.
  43. O’Brien EC, Simon DN, Thomas LE et al. The ORBIT bleeding score: a simple bedside score to assess bleeding risk in atrial fibrillation. Eur Heart J. 2015;36:3258–64.
  44. Hart RG, Eikelboom JW, Brimble KS et al. Stroke prevention in atrial fibrillation patients with chronic kidney disease. Can J Cardiol. 2013;29:S71–78.
  45. Urquhart J, Eisen G, Faigel DO et al. A closer look at same-day bidirectional endoscopy. Gastrointest Endosc. 2009;69:271–7.
  46. Rockey DC, Koch J, Cello JP et al. Relative frequency of upper gastrointestinal and colonic lesions in patients with positive fecal occult-blood tests. N Engl J Med. 1998;339:153–9.
  47. Choi JS, Choi JY, Cho HG et al. Is esophagogastroduodenoscopy necessary in patients with positive fecal occult blood tests and negative colonoscopy? Scand J Gastroenterol. 2013;48:657– 62. doi: 10.3109/00365521.2013.792390.
  48. Paciaroni M, Agnelli G. Should oral anticoagulants be restarted after warfarin –associated cerebral haemorrhage in patients with atrial fibrillation? Thromb Haemost. 2014;111:14–18.
  49. Nielsen PB, Larsen TB, Skjoth F et al. Restarting Anticoagulant Treatment After Intracranial Hemorrhage in Patients With Atrial Fibrillation and the Impact on Recurrent Stroke, Mortality, and Bleeding: A Nationwide Cohort Study. Circulation. 2015;132:517–525.
  50. Yung D, Kapral MK, Asllani E et al. Investigators of the Registry of the Canadian Stroke Network. Reinitiation of anticoagulation after warfarin-associated intracranial hemorrhage and mortality
  51. Lip GY, Nieuwlaat R, Pisters R et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest. 2010;137:263–272.
  52. Olesen JB, Lip GY, Hansen M. Letal Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study. BMJ. 2011;342:d124.
  53. Zhu W, Xiong Q, Hong K. Meta-analysis of CHADS2 versus CHA2DS2-VASc forpredicting stroke and thromboembolism in atrial fibrillation patients independent of anticoagulation, Tex. Heart Inst. J. 2015; 42: 6–15.
  54. Van Staa TP, Setakis E, Di Tanna GL et al. A comparison of risk stratification schemes for stroke in 79,884 atrial fibrillation patients in general practice. J Thromb Haemost. 2011;9:39–48. doi: 10.1111/j.1538-7836.2010.04085.x.
  55. Friberg L, Rosenqvist M, Lip GY. Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study. Eur Heart J. 2012;33:1500–1510.
  56. Pisters R, Lane DA, Nieuwlaat R et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest. 2010;138:1093–1100.
  57. Olesen JB, Lip GY, Hansen PR et al. Bleeding risk in «real world» patients with atrial fibrillation: comparison of two established bleeding prediction schemes in a nationwide cohort. J Thromb Haemost. 2011;9:1460–1467.
  58. Roldan V, Marin F, Manzano-Fernandez S et al The HAS-BLED score has better prediction accuracy for major bleeding than CHADS2 or CHA2DS2-VASc scores in anticoagulated patients with atrial fibrillation. J Am Coll Cardiol.
  59. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007;146:857–867.
  60. Connolly SJ, Eikelboom J, Joyner C et al. AVERROES Steering Committee Investigators. Apixaban in patients with atrial fibrillation. N Engl J Med. 2011;364:806–817.
  61. Connolly SJ, Ezekowitz MD, Yusuf S et al. Randomized Evaluation of Long-Term Anticoagulation Therapy Investigators. Newly identified events in the RE-LY trial. N Engl J Med. 2010;363:1875– 1876.
  62. Joundi RA, Cipriano LE, Sposato LA, Saposnik G. Stroke Outcomes Research Working Group. Ischemic Stroke Risk in Patients with Atrial Fibrillation and CHA2DS2-VASc Score of 1: Systematic Review and Meta-Analysis. Stroke. 2016;47:1364–1367.
  63. Friberg L, Skeppholm M, Terent A. Benefit of anticoagulation unlikely in patients with atrial fibrillation and a CHA2DS2-VASc score of 1. J Am Coll Cardiol. 2015;65:225–232.
  64. Lip GY, Skjoth F, Nielsen PB, Larsen TB. Non-valvular atrial fibrillation patients with none or one additional risk factor of the CHA2DS2-VASc score. A comprehensive net clinical benefit analysis for warfarin, aspirin, or no therapy. Thromb Haemost. 2015;114:826–834.
  65. Chao TF, Liu CJ, Wang KL et al. Should atrial fibrillation patients with 1 additional risk factor of the CHA2DS2-VASc score (beyond sex) receive oral anticoagulation? J Am Coll Cardiol. 2015;65:635–642.
  66. Quinn GR, Severdija ON, Chang Y, Singer DE. Wide Variation in Reported Rates of Stroke Across Cohorts of Patients With Atrial Fibrillation. Circulation. 2017;135:208–219. doi: 10.1161/CIRCULATIONAHA.116.024057.
  67. Sjogren V, Grzymala-Lubanski B, Renlund H. Safety and efficacy of well managed warfarin. A report from the Swedish quality register Auricula. Thromb Haemost. 2015;113:1370–1377.
  68. Connolly SJ, Pogue J, Eikelboom J et al. ACTIVE W Investigators. Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range. Circulation. 2008;118:2029–2037.
  69. Wan Y, Heneghan C, Perera R et al. Anticoagulation control and prediction of adverse events in patients with atrial fibrillation: a systematic review. Circ Cardiovasc Qual Outcomes. 2008;1:84– 91.
  70. De Caterina R, Husted S, Wallentin L et al. Vitamin K antagonists in heart disease: current status and perspectives (Section III). Position paper of the ESC Working Group on Throm-bosis–Task Force on Anticoagulants in Heart Disease. Thromb Haemost. 2013;110:1087–1107.
  71. Vestergaard AS, Skjøth F, Larsen TB, Ehlers LH. The importance of mean time in thera-peutic range for complication rates in warfarin therapy of patients with atrial fibrillation: A systematic review and meta-regression analysis. PLoS One. 2017;12:e0188482. doi: 10.1371/journal.pone.0188482.
  72. Liu S, Li X, Shi Q et al. Outcomes associated with warfarin time in therapeutic range among US veterans with nonvalvular atrial fibrillation. Curr Med Res Opin. 2018;34:415–421. doi: 10.1080/03007995.2017.1384370.
  73. Björck F, Renlund H, Lip GY et al. Outcomes in a Warfarin-Treated Population With Atrial Fibrillation. JAMA Cardiol. 2016;1:172–180. doi: 10.1001/jamacardio.2016.0199.
  74. Кропачева Е.С., Боровков Н.Н., Вавилова Т.В. и др. Быстрые темпы насыщения варфарином–предиктор развития чрезмерной гипокоагуляции. Модернизация алгоритма подбора дозы варфарина // Атеротромбоз. – 2015. – № 1. – С. 74–86.
  75. Панченко Е.П. Антитромботическая терапия в кардиологии. Москва: Ремедиум, 2019. – 255с.
  76. van Doorn S, Debray TPA, Kaasenbrood F et al. Predictive performance of the CHA2DS2-VASc rule in atrial fibrillation: a systematic review and meta-analysis. J Thromb Haemost. 2017 Jun;15(6):1065-1077. doi: 10.1111/jth.13690. Epub 2017 May 9.
  77. Li YG, Miyazawa K, Wolff A et al. One-year risks of stroke and mortality in patients with atrial fibrillation from different clinical settings: The Gulf SAFE registry and Darlington AF registry. Int J Cardiol. 2019 Jan 1;274:158-162. doi: 10.1016/j.ijcard.2018.08.091. Epub 2018 Sep 1
  78. Vestergaard AS, Skjøth F, Larsen TB et al. The importance of mean time in therapeutic range for complication rates in warfarin therapy of patients with atrial fibrillation: A systematic review and meta-regression analysis. PLoS One. 2017 Nov 20;12(11):e0188482. doi: 10.1371/journal.pone.0188482. eCollection 2017.
  79. Liu S, Li X, Shi Q et al.Outcomes associated with warfarin time in therapeutic range among US veterans with nonvalvular atrial fibrillation. Curr Med Res Opin. 2018 Mar;34(3):415-421. doi: 10.1080/03007995.2017.1384370. Epub 2017 Oct 3
  80. Ruff CT, Giugliano RP, Braunwald E et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014;383:955–962.
  81. Kim IS, Kim HJ, Kim TH et al. Non-vitamin K antagonist oral anticoagulants have better efficacy and equivalent safety compared to warfarin in elderly patients with atrial fibrillation: A systematic review and meta-analysis. J Cardiol. 2018;72:105–112. doi: 10.1016/j.jjcc.2018.01.015.
  82. Kim IS, Kim HJ, Kim TH et al. Appropriate doses of non-vitamin K antagonist oral anticoagulants in high-risk subgroups with atrial fibrillation: Systematic review and meta-analysis. J Cardiol. 2018;72:284–291. doi: 10.1016/j.jjcc.2018.03.009.
  83. Ntaios G, Papavasileiou V, Diener HC et al. Nonvitamin-K-antagonist oral anticoagulants versus warfarin in patients with atrial fibrillation and previous stroke or transient ischemic attack: An updated systematic review and meta-analysis of randomized controlled trials. Int J Stroke. 2017;12:589–596. doi: 10.1177/1747493017700663.
  84. Dogliotti A1, Paolasso E, Giugliano RP. Novel oral anticoagulants in atrial fibrillation: a meta-analysis of large, randomized, controlled trials vs warfarin. Clin Cardiol. 2013;36:61–7. doi: 10.1002/clc.22081.
  85. Wallentin L, Yusuf S, Ezekowitz MD et al. RE-LY investigators. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio con-trol for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet. 2010;376:975–983.
  86. Carmo J, Ferreira J, Costa F et al. Non-vitamin K antagonist oral anticoagulants compared with warfarin at different levels of INR control in atrial fibrillation: A meta-analysis of randomized trials Int J Cardiol. 2017 Oct 1;244:196-201. doi: 10.1016/j.ijcard.2017.06.004. Epub 2017 Jun 3;
  87. Dans AL, Connolly SJ, Wallentin L et al. Concomitant use of antiplatelet therapy with dabigatran or warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial. Circulation. 2013;127:634–640.
  88. Lamberts M, Olesen JB, Ruwald MH et al. Bleeding after initiation of multiple antithrombotic drugs, including triple therapy, in atrial fibrillation patients following myocardial infarction and coronary intervention: a nationwide cohort study. Circulation. 2012;126:1185–1193.
  89. Sindet-Pedersen C, Lamberts M, Staerk L et al. Combining Oral Anticoagulants With Platelet Inhibitors in Patients With Atrial Fibrillation and Coronary Disease. J Am Coll Cardiol. 2018;72:1790–1800. doi: 10.1016/j.jacc.2018.07.054.
  90. Lamberts M, Gislason GH, Lip GY et al. Antiplatelet therapy for stable coronary artery disease in atrial fibrillation patients taking an oral anticoagulant: a nationwide cohort study. Circulation. 2014;129:1577–85. doi:10.1161/CIRCULATIONAHA.113.004834
  91. Lip, G., Lindhardsen, J., Lane et al. Risks of thromboembolism and bleeding with thromboprophylaxis in patients with atrial fibrillation: A net clinical benefit analysis using a “real world” nationwide cohort study. Thrombosis and Haemostasis, 106(10), 739–749. doi:10.1160/th11-05-0364
  92. Friberg, L., Rosenqvist, M., Lip, G. et al. Net Clinical Benefit of Warfarin in Patients With Atrial Fibrillation: A Report From the Swedish Atrial Fibrillation Cohort Study. Circulation, 125(19), 2298–2307. doi:10.1161/circulationaha.111.055079
  93. Sjalander S, Sjalander A, Svensson PJ, Friberg L. Atrial fibrillation patients do not benefit from acetylsalicylic acid. Europace. 2014;16:631–638.
  94. Szekely P. Systemic Embolism and Anticoagulant Prophylaxis in Rheumatic Heart Disease. Br Med J. 1964;1:1209–1212.
  95. Eikelboom JW, Connolly SJ, Brueckmann M et al. RE-ALIGN Investigators. Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med. 2013;369:1206–1214.
  96. Perez-Gomez F, AlegriaE, Berjon J et al. NASPEAF Investigators. Comparative effects of antiplatelet, anticoagulant, or combined therapy in patients with valvular and nonvalvular atrial fibrillation: a randomized multicenter study. J Am Coll Cardiol. 2004;44:1557–1566.
  97. Rowe JC, Bland EF, Sprague HB, White PD. The course of mitral stenosis without surgery: ten- and twenty-year perspectives. Ann Intern Med. 1960;52:741–749.
  98. Cannegieter SC, van der Meer FJ, Briet E, Rosendaal FR. Warfarin and aspirin after heart-valve replacement. N Engl J Med. 1994;330:507–508; author reply 508-509.
  99. Сhiang CW, Lo SK, Ko YS et al. Predictors of systemic embolism in patients with mitral stenosis. A prospective study. Ann Intern Med. 1998;128:885–889.
  100. Atar, S., Wishniak, A., Shturman, A., et al. Fatal Association of Mechanical Valve Thrombosis With Dabigatran. Chest, 144(1), 327–328. doi:10.1378/chest.12-2486
  101. Pan KL, Singer DE, Ovbiagele B et al. Effects of non-vitamin K antagonist oral anticoagulants versus warfarin in patients with atrial fibrillation and valvular heart disease: a systematic review and meta-analysis. J Am Heart Assoc. 2017;6:e005835.
  102. Renda G, Ricci F, Giugliano RP, De Caterina R. Non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation and valvular heart disease. J Am Coll Cardiol. 2017;69:1363– 1371.
  103. Noseworthy PA, Yao X, Shah ND, Gersh BJ. Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants versus warfarin in patients with atrial fibrillation and valvular heart disease. Int J Cardiol. 2016;209:181–183.
  104. Cappato R, Ezekowitz MD, Klein AL et al. X-VeRT Investigators. Rivaroxaban vs. vitamin K antagonists for cardioversion in atrial fibrillation. Eur Heart J. 2014;35:3346–3355.
  105. Nagarakanti R, Ezekowitz MD, Oldgren J et al. Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion. Circulation. 2011;123:131–136.
  106. Nuotio I, Hartikainen JE, Gronberg T et al. Time to cardioversion for acute atrial fibrillation and thromboembolic complications. JAMA. 2014;312:647–649
  107. Hansen M. L., Jepsen R. M. H. G., Olesen J. B. et al. Thromboembolic risk in 16,274atrial fibrillation patients undergoing direct current cardioversion with and without o Europace. 2015;17:18-23
  108. Ezekowitz MD; Pollack C.V. Jr; Halperin J.L.; et al. Apixaban compared to heparin/vitamin K antagonist in patients with atrial fibrillation scheduled for cardioversion: the EMANATE trial. Eur Heart J 2018; 39: 2959-2971
  109. Cappato R, Ezekowitz MD, Klein AL, et al. Rivaroxaban vs. vitamin K antagonists for cardioversion in atrial fibrillation. European Heart Journal 2014:35 (47); 3346–3355
  110. Steinberg JS, Sadaniantz A, Kron J et al. Analysis of cause-specific mortality in the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study. Circulation. 2004;109:1973–1980.
  111. Henrik V, Peter BN, Søren PH et al. Atrial Flutter and Thromboembolic Risk: A Systematic Review Heart. 2015 Sep;101(18):1446-55. doi: 10.1136/heartjnl-2015-307550. Epub 2015 Jul 6. PMID: 26149627 DOI: 10.1136/heartjnl-2015-307550
  112. Klein AL, Grimm RA, Murray RD Klein AL, Grimm RA, Murray RD et al. Use of transesophageal echocardiography to guide cardioversion in patients with atrial fibrillation. N Engl J Med. 2001;344:1411–1420.
  113. Paciaroni M, Agnelli G, Micheli S, Caso V. Efficacy and safety of anticoagulant treatment in acute cardioembolic stroke: a meta-analysis of randomized controlled trials. Stroke. 2007;38:423–430.
  114. Paciaroni M1, Agnelli G, Corea F et al. Early hemorrhagic transformation of brain infarction: rate, predictive factors, and influence on clinical outcome: results of a prospective multicenter study. Stroke. 2008;39:2249–56. doi: 10.1161/STROKEAHA.107.510321.
  115. Tan S, Wang D, Liu M et al. Frequency and predictors of spontaneous hemorrhagic transformation in ischemic stroke and its association with prognosis. J Neurol. 2014;261:905– 12. doi: 10.1007/s00415–014–7297–8.
  116. Hong KS, Kwon SU, Lee SH et al. Rivaroxaban vs Warfarin Sodium in the Ultra-Early Period After Atrial Fibrillation–Related Mild Ischemic Stroke. A Randomized Clinical Trial JAMA Neurol. 2017;74:1206–1215. doi: 10.1001/jamaneurol.2017.2161.
  117. Seiffge DJ, Traenka C, Polymeris A et al. Early start of DOAC after ischemic stroke: Risk of intracranial hemorrhage and recurrent events. Neurology. 2016;87:1856–1862.
  118. Macha K, Volbers B, Bobinger T et al. Early Initiation of Anticoagulation with Direct Oral Anticoagulants in Patients after Transient Ischemic Attack or Ischemic Stroke. J Stroke Cerebrovasc Dis. 2016;25:2317–21. doi: 10.1016/j.jstrokecerebrovasdis.2016.06.031.
  119. CAST (Chinese Acute Stroke Trial) Collaborative Group. CAST: randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. Lancet. 1997 Jun 7;349(9066):1641-9. PMID: 9186381.
  120. The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. International Stroke Trial Collaborative Group. Lancet. 1997 May 31;349(9065):1569-81.
  121. Diener HC, Stanford S, Abdul-Rahim A et al. Anti-thrombotic therapy in patients with atrial fibrillation and intracranial hemorrhage. Expert Rev Neurother. 2014;14:1019–1028.
  122. Xian Y, Liang L, Smith EE et al. Risks of intracranial hemorrhage among patients with acute ischemic stroke receiving warfarin and treated with intravenous tissue plasminogen activator. JAMA. 2012;307:2600–2608.
  123. Powers WJ, Rabinstein AA, Ackerson T et al. American Heart Association Stroke Council. 2018 guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2018;49:e46–e99.
  124. Giannandrea D, Caponi C, Mengoni A et al. Intravenous thrombolysis in stroke after dabigatran reversal with idarucizumab: case series and systematic review. J Neurol Neurosurg Psychiatry. 2019;90:619–623. doi:10.1136/jnnp-2018–318658.
  125. Diener HC, Eikelboom J. Apixaban versus aspirin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a predefined subgroup analysis from AVERROES, a randomised trial. Lancet Neurol. 2012;11:225–231.
  126. Ntaios G, Papavasileiou V, Diener HC et al. Nonvitamin-K-antagonist oral anticoagulants in patients with atrial fibrillation and previous stroke or transient ischemic attack: a systematic review and meta-analysis of randomized controlled trials. Stroke. 2012;43:3298–3304.
  127. Mant J, Hobbs FD, Fletcher Ketal. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet. 2007;370:493–503.
  128. Woo D, Haverbusch M, Sekar P, et al. Effect of Untreated Hypertension on Hemorrhagic Stroke. Stroke. 2004;35:1703–1708.
  129. Flaker GC, Gruber M, Connolly SJ et al. Risks and benefits of combining aspirin with anticoagulant therapy in patients with atrial fibrillation: an exploratory analysis of stroke prevention using an oral thrombin inhibitor in atrial fibrillation (SPORTIF) trials. Am Heart J. 2006;152:967–973.
  130. SPAF I-III = Hart RG, Pearce LA, McBride R, et al “Factors associated with ischemic stroke during aspirin therapy in atrial fibrillation: analysis of 2012 participants in the SPAF I-III clinical trials. The Stroke Prevention in Atrial Fibrillation (SPAF) Investigators” Stroke 1999 Jun;30(6):1223-9
  131. AFASAK 2 = A.L.Gullov, MD, B.G.Koefoed,MD, P.Petersen, DMSc et al “Fixed minidose warfarin and aspirin alone and in combination versus adjusted-dose warfarin for stroke prevention in atrial fibrillation” Arch Intern Med 1998;158:1513-1521 RE-LY (sub-analysis)DOI: 10.1161/CIRCULATIONAHA.112.115386;
  132. Olesen JB, Lip GY, Lindhardsen J, et al. Risks of thromboembolism and bleeding with thromboprophylaxis in patients with atrial fibrillation: A net clinical benefit analysis using a "real world" nationwide cohort study. Thromb Haemost. 2011;106(4):739‐749. doi:10.1160/TH11-05-0364
  133. Majeed A, Kim YK, Roberts RS, Holmström M, Schulman S. Optimal timing of resumption of warfarin after intracranial hemorrhage. Stroke. 2010;41:2860–2866. doi: 10.1161/STROKEAHA.110.593087
  134. Murthy S. B., Gupta A., Merkler A. E. et al. Restarting Anticoagulant Therapy After Intracranial Hemorrhage. Stroke, 48(6), 1594–1600. doi:10.1161/strokeaha.116.016327
  135. Pollack CV Jr., Reilly PA, van Ryn J et al. Еdarucizumab for dabigatran reversal – Full cohort analysis. N Engl J Med. 2017;377:431–41.
  136. Feldman DN, Wang TY, Chen AY et al. In-Hospital Bleeding Outcomes of Myocardial Infarction in the Era of Warfarin and Direct Oral Anticoagulants for Atrial Fibrillation in the United States: A Report From the National Cardiovascular Data Registry Acute Coronary Treatment and Intervention Outcomes Network Registry. J Am Heart Assoc. 2019;8:e011606. doi:10.1161/JAHA.118.011606.
  137. Pollack CV. Coagulation assessment with the new generation of oral anticoagulants. Emerg Med J. 2016;33:423–30. doi:10.1136/emermed-2015–204891.
  138. I. Hernandez, Y. Zhang, M.M. Brooks, et al. Anticoagulation use and clinical outcomes after major bleeding on dabigatran or warfarin in atrial fibrillation. Stroke. 2017; 48:159-166.
  139. Kuramatsu JB, Gerner ST, Schellinger PD et al. Anticoagulant reversal, blood pressure levels, and anticoagulant resumption in patients with anticoagulation-related intracerebral hemorrhage. JAMA. 2015;313:824–836.
  140. Witt DM, Delate T, Garcia DA et al. Risk of thromboembolism, recurrent hemorrhage, and death after warfarin therapy interruption for gastrointestinal tract bleeding. Arch Intern Med. 2012;172:1484–91. doi: 10.1001/archinternmed.2012.4261.
  141. Staerk L, Lip GY, Olesen JB et al. Stroke and recurrent haemorrhage associated with antithrombotic treatment after gastrointestinal bleeding in patients with atrial fibrillation: nationwide cohort study. BMJ. 2015;351:h5876.
  142. Felmeden DC, Lip GY. Antithrombotic therapy in hypertension: a Cochrane Systematic review. J Hum Hypertens. 2005;19:185–196.
  143. Graham DJ, Reichman ME, Wernecke M et al. Cardiovascular, bleeding, and mortality risks in elderly medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation. Circulation. 2015;131: 157–164.
  144. Hylek EM, Held C, Alexander JH et al. Major bleeding in patients with atrial fibrillation receiving apixaban or warfarin: The ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation): Predictors, Characteristics, and Clinical Outcomes. J Am Coll Cardiol. 2014;63:2141–2147.
  145. Eikelboom JW, Wallentin L, Connolly SJ et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation. 2011;123:2363–2372.
  146. Chang HY, Zhou M, Tang W, Alexander GC, Singh S. Risk of gastrointestinal bleeding associated with oral anticoagulants: population based retrospective cohort study. BMJ. 2015;350:h1585.
  147. Abraham NS, Singh S, Alexander GC et al. Comparative risk of gastrointestinal bleeding with dabigatran, rivaroxaban, and warfarin: population based cohort study. BMJ. 2015;350:h1857.
  148. Sharma M, Cornelius VR, Patel JP et al. Efficacy and Harms of Direct Oral Anticoagulants in the Elderly for Stroke Prevention in Atrial Fibrillation and Secondary Prevention of Venous Thromboembolism: Systematic Review and Meta-Analysis. Circulation. 2015;132:194–204.
  149. Sherwood MW, Nessel CC, Hellkamp AS, et al. Gastrointestinal Bleeding in Patients With Atrial Fibrillation Treated With Rivaroxaban or Warfarin: ROCKET AF Trial. J Am Coll Cardiol. 2015;66(21):2271-2281. doi: 10.1016/j.jacc.2015.09.024.
  150. Miller CS, Dorreen A, Martel M, et al. Risk of Gastrointestinal Bleeding in Patients Taking Non-Vitamin K Antagonist Oral Anticoagulants: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol. 2017;15(11):1674-1683
  151. Palareti G, Cosmi B. Bleeding with anticoagulation therapy – who is at risk, and how best to identify such patients. Thromb Haemost. 2009;102:268–278.
  152. Tse G, Gong M, Li G et al. Genotype-guided warfarin dosing vs. conventional dosing strategies: a systematic review and meta-analysis of randomized controlled trials. Br J Clin Pharmacol. 2018;84:1868–1882. doi: 10.1111/bcp.13621.
  153. Yang T, Zhou Y, Chen C et al. Genotype-guided dosing versus conventional dosing of warfarin: A meta-analysis of 15 randomized controlled trials. J Clin Pharm Ther. 2019;44:197–208. doi: 10.1111/jcpt.12782.
  154. Stergiopoulos K, Brown DL. Genotype-guided vs clinical dosing of warfarin and its analogues: meta-analysis of randomized clinical trials. JAMA Intern Med. 2014;174:1330–8. doi: 10.1001/jamainternmed.2014.2368
  155. Эрлих А.Д. Острый коронарный синдром без подъемов сегмента ST в практике российских стационаров: сравнительные данные регистров РЕКОРД-2 и РЕКОРД. // Кардиология. – 2012. – № 10. – С. 9–16.
  156. Батурина О.А. Распространенность фибрилляции предсердий при остром коронарном синдроме и особенности назначения пероральных антитромботических препаратов. // Кардиология. – 2019. – № 1. – С. 40–48.
  157. Sarafoff N, Martischnig A, Wealer J et al. Triple therapy with aspirin, prasugrel, and vitamin K antagonists in patients with drug-eluting stent implantation and an indication for oral anticoagulation. J Am Coll Cardiol. 2013;61:2060–2066.
  158. Lip GYH, Collet JP, Haude M, et al. 2018 Joint European consensus document on the management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous cardiovascular interventions: a joint consensus document of the European Heart Rhythm Association (EHRA), European Society of Cardiology Working Group on Thrombosis, European Association of Percutaneous Cardiovascular Interventions (EAPCI), and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS), Latin
  159. Koskinas KC, Räber L, Zanchin T et al. Duration of Triple Antithrombotic Therapy and Outcomes Among Patients Undergoing Percutaneous Coronary Intervention. JACC Cardiovasc Interv. 2016;9:1473–83. doi: 10.1016/j.jcin.2016.04.027.
  160. Fiedler KA, Maeng M, Mehilli J. Duration of Triple Therapy in Patients Requiring Oral Anticoagulation After Drug-Eluting Stent Implantation: The ISAR-TRIPLE Trial. J Am Coll Cardiol. 2015;65:1619–1629. doi: 10.1016/j.jacc.2015.02.050.
  161. Alexander JH, Wojdyla D, Vora AN, et al. The Risk/Benefit Tradeoff of Antithrombotic Therapy in Patients With Atrial Fibrillation Early and Late After an Acute Coronary Syndrome or Percutaneous Coronary Intervention: Insights From AUGUSTUS. Circulation 2020;Mar 29].
  162. Rossini R, Musumeci G, Lettieri C, et al. Long-term outcomes in patients undergoing coronary stenting on dual oral antiplatelet treatment requiring oral anticoagulant therapy. Am J Cardiol. 2008;102(12):1618-1623. doi:10.1016/j.amjcard.2008.08.021
  163. Lopes RD, Heizer G, Aronson R et al. Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation. N Engl J Med. 2019;380:1509–1524.
  164. Al-Khatib SM, Allen LaPointe NM, Chatterjee R et al. Rate- and rhythm-control therapies in patients with atrial fibrillation: a systematic review. Ann Intern Med. 2014;160:760–773.
  165. Chatterjee S, Sardar P, Lichstein E et al. Pharmacologic rate versus rhythm-control strategies in atrial fibrillation: an updated comprehensive review and meta-analysis. PACE. 2013;36:122–133.
  166. Van Gelder IC, Groenveld HF, Crijns HJ et al. Lenient versus strict rate control in patients with atrial fibrillation. N Engl J Med. 2010;362:1363–1373.
  167. Farshi R, Kistner D, Sarma JS et al. Ventricular rate control in chronic atrial fibrillation during daily activity and programmed exercise: a crossover open-label study of five drug regimens. J Am Coll Cardiol. 1999;33:304–310.
  168. Groenveld HF, Tijssen JG, Crijns HJ et al. RACE II Investigators. Rate control efficacy in permanent atrial fibrillation: successful and failed strict rate control against a background of lenient rate control: data from RACE II (Rate Control Efficacy in Permanent Atrial Fibrillation). J Am Coll Cardiol. 2013;61:741–748. doi: 10.1016/j.jacc.2012.11.038.
  169. Ziff OJ, Lane DA, Samra M et al. Safety and efficacy of digoxin: systematic review and meta-analysis of observational and controlled trial data. BMJ. 2015;351:h4451.
  170. Allen LA, Fonarow GC, Simon DN et al. ORBIT‐AF Investigators. Digoxin use and subsequent outcomes among patients in a contemporary atrial fibrillation cohort. J Am Coll Cardiol. 2015;65:2691–2698.
  171. Yu HT, Yang PS, Lee H et al. Outcomes of Rate-Control Treatment in Patients With Atrial Fibrillation and Heart Failure – A Nationwide Cohort Study. Circ J. 2018;82:652–658. doi: 10.1253/circj.CJ-17–0669.
  172. Gheorghiade M, Fonarow GC, van Veldhuisen DJ et al. Lack of evidence of increased mortality among patients with atrial fibrillation taking digoxin: findings from post hoc propensity-matched analysis of the AFFIRM trial. Eur Heart J. 2013;34:1489–1497.
  173. Andrey JL, Romero S, Garcia-Egido A et al. Mortality and morbidity of heart failure treated with digoxin. A propensity-matched study. Int J Clin Pract. 2011;65:1250–1258.
  174. Zehender M, Hohnloser S, Muller B et al. Effects of amiodarone versus quinidine and verapamil in patients with chronic atrial fibrillation: Results of a comparative study and a 2-year follow-up. J Am Coll Cardiol. 1992;19:1054–1059.
  175. Tse HF, Lam YM, Lau CP et al. Comparison of digoxin versus low-dose amiodarone for ventricular rate control in patients with chronic atrial fibrillation. Clin Exp Pharmacol Physiol. 2001;28:446-450.
  176. Gulamhusein S, Ko P, Carruthers SG, Klein GJ. Acceleration of the ventricular response during atrial fibrillation in the Wolff – Parkinson – White syndrome after verapamil. Circulation. 1982;65:348–354.
  177. Crijns HJ, Weijs B, Fairley AM et al. Contemporary real life cardioversion of atrial fibrillation: Results from the multinational RHYTHM-AF study. Int J Cardiol. 2014;172: 588–594.
  178. Coll-Vinent B, Sala X, Fernandez C et al. Sedation for cardioversion in the emergency department: analysis of effectiveness in four protocols. Ann Emerg Med. 2003;42:767–772. 2012;380:238–246.
  179. Singh BN, Singh SN, Reda DJ et al. Amiodarone versus sotalol for atrial fibrillation. N Engl J Med. 2005;352:1861–1872.
  180. Kirchhof P, Eckardt L, Loh P et al. Anterior-posterior versus anteriorlateral electrode positions for external cardioversion of atrial fibrillation: a randomized trial. Lancet. 2002;360:1275–1279.
  181. Kirchhof P, Monnig G, Wasmer K et al. A trial of self-adhesive patch electrodes and hand-held paddle electrodes for external cardioversion of atrial fibrillation (MOBIPAPA). Eur Heart J. 2005;26:1292–7.
  182. Klein AL, Grimm RA, Murray RD et al. Use of transesophageal echocardiography to guide cardioversion in patients with atrial fibrillation. N Engl J Med. 2001;344:1411–1420,1292–1297.
  183. Goldner BG, Baker J, Accordino A et al. Electrical cardioversion of atrial fibrillation or flutter with conscious sedation in the age of cost containment. Am Heart J. 1998;136:961–964.
  184. Kleemann T, Becker T, Strauss M, Schneider S, Seidl K. Prevalence of left atrial thrombus and dense spontaneous echo contrast in patients with short-term atrial fibrillation < 48 hours undergoing cardioversion: value of transesophageal echocardiography to guide cardioversion. J Am Soc Echocardiogr. 2009;22(12):1403-1408. doi:10.1016/j.echo.2009.09.015
  185. Hagens VE, Ranchor AV, Van Sonderen E et al. Effect of rate or rhythm control on quality of life in persistent atrial fibrillation: results from the Rate Control Versus Electrical Cardioversion (RACE) Study. J Am Coll Cardiol. 2004;43:241–7.
  186. Alboni P, Botto GL, Baldi N et al. Outpatient treatment of recent-onset atrial fibrillation with the «pill-in-the-pocket» approach. N Engl J Med. 2004;351:2384–2391.
  187. Del Arco C, Martin A, Laguna P et al. Analysis of current management of atrial fibrillation in the acute setting: GEFAUR-1 study. Ann Emerg Med. 2005;46:424–430.
  188. Khan IA. Single oral loading dose of propafenone for pharmacological cardioversion of recent-onset atrial fibrillation. J Am Coll Cardiol. 2001;37:542–7.
  189. Saborido CM, Hockenhull J, Bagust A et al. Systematic review and cost-effectiveness evaluation of «pill-in-the-pocket» strategy for paroxysmal atrial fibrillation compared to episodic in-hospital treatment or continuous antiarrhythmic drug therapy. Health Technol Assess. 2010;14:iii–iv,1–75.
  190. Беннетт Д.Х. Аритмии сердца. Практические заметки по интерпретации и лечению. – Москва: Медпресс-информ, 2016. – С. 32–49.
  191. Кушаковский М.С. Аритмии сердца. – С.-Петербург: Фолиант, 2007. – С. 531–576.
  192. Недоступ А.В., Благова О.В. Как лечить аритмии. Диагностика и терапия нарушений ритма и проводимости в клинической практике. – Москва: МЕДпресс-информ, 2007. – С. 21–107.
  193. Josephson ME. Clinical cardiac electrophysiology. Techniques and interpretation. Philadelphia, PA: Lippincott Williams and Wilkins, 2008. pp: 285–339; 339–446.
  194. Manios EG, Mavrakis HE, Kanoupakis EM et al. Effects of amiodarone and diltiazem on persistent atrial fibrillation conversion and recurrence rates: a randomized controlled study. Cardiovasc Drugs Ther. 2003;17:31–3.
  195. Bianconi L, Mennuni M, Lukic V et al. Effects of oral propafenone administration before electrical cardioversion of chronic atrial fibrillation: a placebo-controlled study. JACC. 1996;28:700–70.
  196. Roth A, Elkayam I, Shapira I et al. Effectiveness of prehospital synchronous direct-current cardioversion for supraventricular tachyarrhythmias causing unstable hemodynamic states. Am J Cardiol. 2003;91:489491.
  197. Scheuermeyer FX, Grafstein E, Heilbron B, Innes G. Emergency department management and 1-year outcomes of patients with atrial flutter. AnnEmergMed 2011; 57:564–571.e2.
  198. Kirchhof P, Andresen D, Bosch R et al. Short-term versus ong-term antiarrhythmic drug treatment after cardioversion of atrial fibrillation (Flec-SL): a prospective, randomised, open-label, blinded endpoint assessment trial. Lancet.
  199. Olasveengen TM, de Caen AR, Mancini ME et al. ILCOR Collaborators. 2017 international consensus on cardiopulmonary resuscitation and emergency cardiovascular care science with treatment recommendations summary. Circulation. 2017;136:e424e440.
  200. Zhang N, Guo JH, Zhang H et al. Comparison of intravenous ibutilide vs. propafenone for rapid termination of recent onset atrial fibrillation. Int J Clin Pract. 2005;59:1395–1400.
  201. Martinez-Marcos FJ, Garcia-Garmendia JL, Ortega-Carpio A et al. Comparison of intravenous flecainide, propafenone, and amiodarone for conversion of acute atrial fibrillation to sinus rhythm. Am J Cardiol. 2000;86:950–953
  202. Halpern SW, Ellroot G, Singh BN et al. Efficacy of intravenous procainamid infusion in converting atrial fibrillation to sinus rhythm. Relation to left atrium size. Brit Heart J. 1980;44:589–595.
  203. Fenster PE, Comess KA, Marsh A et al. Conversion of atrial fibrillation to sinus rhythm by acute intravenous procainamide infusion. Am Heart J. 1983;106:501–504.
  204. Kochiadakis GE, Igoumenidis NE, Solomou MC et al. Conversion of atrial fibrillation to sinus rhythm using acute intravenous procainamide infusion. Cardiovasc Drugs Ther. 1998;12:75–81.
  205. Kochiadakis GE, Igoumenidis NE, Hamilos ME et al. A comparative study of the efficacy and safety of procainamide versus propafenone versus amiodarone for the conversion of recent-onset atrial fibrillation. Am J Cardiol. 2007;99:1721–1725.
  206. Stiell IG, Clement CM, Symington C et al. Emergency department use of intravenous procainamide for patients with acute atrial fibrillation or flutter. Acad Emerg Med. 2007;14:1158–1164.
  207. Chevalier P, Durand-Dubief A, Burri H et al. Amiodarone versus placebo and class Ic drugs for cardioversion of recent-onset atrial fibrillation: a meta-analysis. JACC. 2003;41:255–262.
  208. Vardas PE, Kochiadakis GE, Igoumenidis NE et al. Amiodarone as a first-choice drug for restoring sinus rhythm in patients with atrial fibrillation: a randomized, controlled study. Chest. 2000;117:1538–1545.
  209. Bianconi L, Castro A, Dinelli M et al. Comparison of intravenously administered dofetilide versus amiodarone in the acute termination of atrial fibrillation and flutter. A multicentre, randomized, double-blind, placebo-controlled study. Eur Heart J. 2000;21:1265–1273.
  210. Юричева Ю.А., Соколов С.Ф., Голицын С.П. и др. Новый антиаритмический препарат III класса ниферидил как эффективное средство восстановления синусового ритма при персистирующей форме мерцательной аритмии. // Вестник аритмологии. – 2012. – № 70. – С. 32–43.
  211. Миронов Н.Ю., Влодзяновский В.В., Юричева Ю.А. и соавт. Проспективное рандомизированное исследование эффективности и безопасности электрической и медикаментозной кардиоверсии при персистирующей фибрилляции предсердий. Часть 2: оценка безопасности. Рациональная фармакотерапия в кардиологии. 2018;14(6):826-830. doi: 10.20996/1819–6446–2018–14–6–826–830.
  212. Mironov NY, Vlodzyanovskiy VV, Yuricheva YA et al. Safety and Effectiveness of Electrical and Pharmacological Cardioversion in Persistent Atrial Fibrillation. Part 2: Assessment of Safety. Rational Pharmacotherapy in Cardiology. 2018;14:826–830. doi:10.20996/1819–6446–2018–14– 6–826–830.
  213. Миронов Н.Ю., Влодзяновский В.В., Юричева Ю.А. и соавт. Проспективное рандомизированное исследование эффективности и безопасности электрической и медикаментозной кардиоверсии при персистирующей фибрилляции предсердий. Часть 1: методология исследования и оценка эффективности. Рациональная Фармакотерапия в Кардиологии. 2018;14(5):664-669. https://doi.org/10.20996/1819-6446-2018-14-5-664-669.
  214. Mironov NY, Vlodzyanovskiy VV, Yuricheva YA et al. Safety and Effectiveness of Electrical and Pharmacological Cardioversion in Persistent Atrial Fibrillation. Part I: Study Rationale, Design and Assessment of Effectiveness. Rational Pharmacotherapy in Cardiology. 2018;14:664–669. In russ. doi: 10.20996/1819–6446–2018–14–5-664–669.
  215. Олесин А.И., Смолин З.Ю., Коновалова О.А. и др. Оценка эффективности чреспищеводной электрокардиостимуляции для купирования впервые выявленного трепетания предсердий 1-го типа у больных ишемической болезнью сердца. // Терапевтический архив. – 2009. – № 9. – С. 37–41.
  216. Jacob I, Haft MD, Bernard D, Kosowsky MD et al. Termination of atrial flutter by rapid electrical pacing of the atrium. J Am Coll Cardiol. 1967;20:239–244.
  217. Зинченко Ю.В. Влияние частоты предсердных волн на эффективность чреспищеводной электрокардиостимуляции у больных с изолированным трепетанием предсердий. // Украинский кардиологический журнал. – 2010. – № 2. – С. 61–67.
  218. Сулимов В.А., Дубровский И.А., Канорский С.Г. и др. Чреспищеводная электрическая стимуляция сердца. – Москва, 2015. – 216 с.
  219. Gerd Fröhlig, Semi Sen, Gerd Rettig et al. Termination of atrial flutter during DDD pacing by rapid overdrive stimulation using the implanted pacemaker lead system. J Am Coll Cardiol. 1986;57:483–485. doi: 10.1016/0002–9149(86)90781–2.
  220. Peters RW, Weiss DN, Carliner NH et al. Overdrive pacing for atrial flutter. Am J Cardiol. 1994;74:1021–3.
  221. Peters RW, Shorofsky SR, Pelini M et al. Overdrive atrial pacing for conversion of atrial flutter: comparison of postoperative with nonpostoperative patients. Am Heart J. 1999;137:100.
  222. AFFIRM Investigators. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med. 2002;347:1825–183
  223. Van Gelder IC, Hagens VE, Bosker HA et al. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med. 2002;347:1834–1840.
  224. Roy D, Talajic M, Dorian P et al. Amiodarone to prevent recurrence of atrial fibrillation. Canadian Trial of Atrial Fibrillation Investigators. N Engl J Med. 2000;342:913–920.
  225. Roy D, Talajic M, Nattel S et al. Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med. 2008;358:2667–2677.
  226. Kirchhof P, Bax J, Blomstrom-Lundquist C et al. Early and comprehensive management of atrial fibrillation: executive summary of the proceedings from the 2nd AFNET-EHRA consensus conference ‘research perspectives in AF’. Eur Heart J. 2009;30:2969–2977.
  227. Wilber DJ, Pappone C, Neuzil P et al. ThermoCool AF Trial Investigators. Comparison of antiarrhythmic drug therapy and radiofrequency catheter ablation in patients with paroxysmal atrial fibrillation: a randomized controlled trial. JAMA. 2010;303:333–340.
  228. Lafuente-Lafuente C, Longas-Tejero MA, Bergmann JF et al. Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation. Cochrane Database Syst Rev. 2012;5:CD005049.
  229. Pathak RK, Middeldorp ME, Lau DH et al. Aggressive risk factor reduction study for atrial fibrillation and implicationsfor the outcome of ablation: the ARREST-AF cohort study. J Am Coll Cardiol. 2014;64:2222–2231.
  230. Abed HS, Wittert GA, Leong DP et al. Effect of weight reduction and cardiometabolic risk factor managementon symptom burden and severity in patients with atrial fibrillation: a randomized clinical trial. JAMA. 2013;310:2050–2060.
  231. Pathak RK, Middeldorp ME, Meredith M et al. Long-Term Effect of Goal-Directed Weight Management in an Atrial Fibrillation Cohort: A Long-Term Follow-Up Study (LEGACY). J Am Coll Cardiol. 2015;65:2159–2169.
  232. S.K. Westcott, L.Y Beach, F. Matsushita et al. Relationship Between Psychosocial Stressors and Atrial Fibrillation in Women >45 Years of Age. Am J Cardiol 2018:122(10):1684-1687
  233. Singh SN, Fletcher RD, Fisher SG et al. Amiodarone in patients with congestive heart failure and asymptomatic. Survival ventricular arrhythmia Trial of Antiarrhythmic Therapy in Congestive Heart Failure. N Engl J Med. 1995;333:77–82
  234. AFFIRM study investigators. Maintenance of sinus rhythm in patients with atrial fibrillation: an AFFIRM substudy of the first antiarrhythmic drug. J Am Coll Cardiol. 2003;42:20–9.
  235. Singh BN, Singh SN, Reda DJ et al. Amiodarone versus sotalol for atrial fibrillation. N Engl J Med. 2005;352:1861–72.
  236. Lafuente-Lafuente C, Mouly S, Longas-Tejero MA et al. Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation. Cochrane Database Syst Rev. 2007;4:CD005049.
  237. Channer KS, Birchall A, Steeds RP et al. A randomized placebo-controlled trial of pre-treatment and short- or long-term maintenance therapy with amiodarone supporting DC cardioversion for persistent atrial fibrillation. Eur Heart J. 2004;25:144–50.
  238. Galperin J, Elizari MV, Chiale PA et al. Efficacy of amiodarone for the termination of chronic atrial fibrillation and maintenance of normal sinus rhythm: a prospective, multicenter, randomized, controlled, double blind trial. J Cardiovasc Pharmacol Ther. 2001;6:341–50.
  239. Freemantle N, Lafuente-Lafuente C, Mitchell S et al. Mixed treatment comparison of dronedarone, amiodarone, sotalol, flecainide and propafenone, for the management of atrial fibrillation. Europace. 2011;13:329–45.
  240. Goldschlager N, Epstein AE, Naccarelli GV et al. Practical guide for clinicians who treat patients with amiodarone: 2007. Heart Rhythm. 2007;4:1250–1259.
  241. Wolkove N, Baltzan M. Amiodarone pulmonary toxicity. Can Respir J. 2009;16:43–48.
  242. Fetsch T, Bauer P, Engberding R et al. Prevention of atrial fibrillation after cardioversion: results of the PAFAC trial. Eur Heart J. 2004;25:1385–1394.
  243. Bellandi F, Simonetti I, Leoncini M et al. Long-term efficacy and safety of propafenone and sotalol for the maintenance of sinus rhythm after conversion of recurrent symptomatic atrial fibrillation. Am J Cardiol. 2001;88:640–5. d,l-sotalol therapy in patients with symptomatic atrial fibrillation and/or atrial flutter. d,l- Sotalol Atrial Fibrillation/Flutter Study Group. Am J Cardiol. 1999;84:270–7.
  244. Benditt DG, Williams JH, Jin J et al. Maintenance of sinus rhythm with oral
  245. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med. 1989;321:406–412.
  246. Stroobandt R, Stiels B, Hoebrechts R. Propafenone for conversion and prophylaxis of atrial fibrillation. Propafenone Atrial Fibrillation Trial Investigators. Am J Cardiol. 1997;79:418–423.
  247. Dogan A, Ergene O, Nazli C et al. Efficacy of propafenone for maintaining sinus rhythm in patients with recent onset or persistent atrial fibrillation after conversion: a randomized, placebo-controlled study. Acta Cardiol. 2004;59:255–61.
  248. Соколов С.Ф. Результаты клинического изучения препарата аллапинин и современные подходы к лечению больных с нарушениями ритма сердца. Вестник аритмологии 2011; 64: 60-70;
  249. Pritchett EL, Page RL, Carlson M et al. Efficacy and safety of sustainedrelease propafenone (propafenone SR) for patients with atrial fibrillation. Am J Cardiol. 2003;92:941–6.
  250. Курбанов Р.Д., Абдуллаев Т.А. Фармакодинамика и эффективность аллапинина у больных с нарушениями ритма сердца. // Клиническая медицина. – 1988; – № 10. – С. 52–55.
  251. Каверина Н.В., Лысковцев В.В., Сенова З.П. и др. Этацизин: фармакологические свойства и перспективы клинического применения. // Кардиология. – 1984. – № 5. – С. 52–57.
  252. Недоступ А.В., Благова О.В. Этацизин: место в лечении аритмий. // Кардиология и сердечно-сосудистая хирургия. – 2009. – № 4. – С. 62–68.
  253. Кукес В.Г., Шугушев Х.Х., Гнеушев Е.Т. и др. Фармакокинетика и фармакодинамика нового антиаритмического препарата этацизина® при приеме внутрь. // Советская медицина. – 1985. – № 4. – С. 81–82.
  254. Лозинский Л.Г., Замотаев И.П., Керимова Р.Э. и др. Результаты лечения пароксизмальной мерцательной аритмии этацизином®. // Кардиология. – 1989. – № 7. – С. 37–40.
  255. Echt DS, Liebson PR, Mitchell LB et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo: the Cardiac Arrhythmia Suppression Trial.N Engl J Med.1991;324:781–8.
  256. Olshansky B, Rosenfeld LE, Warner AL et al. The Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study approaches to control rate in atrial fibrillation. J Am Coll Cardiol. 2004;43:1201–8.
  257. Nergardh AK, Rosenqvist M, Nordlander R et al. Maintenance of sinus rhythm with metoprolol CR initiated before cardioversion and repeated cardioversion of atrial fibrillation: a randomized double-blind placebocontrolled study. Eur Heart J. 2007;28:1351–7.
  258. Koh KK, Song JH, Kwon KS, et al. Comparative study of efficacy and safety of low-dose diltiazem or betaxolol in combination with digoxin to control ventricular rate in chronic atrial fibrillation: randomized crossover study. Int J Cardiol 1995;52:167–74
  259. Farshi R, Kistner D, Sarma JS et al. Ventricular rate control in chronic atrial fibrillation during daily activity and programmed exercise: a crossover open-label study of five drug regimens. J Am Coll Cardiol 1999;33:304–10
  260. de Denus S, Sanoski CA, Carlsson J, Opolski G, Spinler SA. Rate vs rhythm control in patients with atrial fibrillation: a meta-analysis. Arch Intern Med 2005;165: 258–262
  261. Sellers TD Jr, Bashore TM, Gallagher JJ. Digitalis in the pre-excitation syndrome. Analysis during atrial fibrillation. Circulation 1977;56:260267. Manolis AS, Estes NA III. Supraventricular tachycardia. Mechanisms and therapy. Arch Intern Med 1987;147:1706–1716
  262. Aronow, W. S. (2008). Treatment of Atrial Fibrillation and Atrial Flutter. Cardiology in Review. 2008; 16(5): 230-239. doi:10.1097/crd.0b013e3181723694 ;
  263. Morris JJ Jr, Peter RH, McIntosh HD. Electrical conversion of atrial fibrillation: immediate and long-term results and selection of patients. Ann Intern Med. 1966;65:216 –231
  264. Singh SN, Tang XC, Reda D et al. Systematic electrocardioversion for atrial fibrillation and role of antiarrhythmic drugs: a substudy of the SAFE-T trial. Heart Rhythm 2009;6:152–155
  265. Hellman T, Kiviniemi T, Nuotio I et al. Optimal timing for cardioversion in patients with atrial fibrillation. Clin Cardiol. 2018; 41(7):966-971. doi: 10.1002/clc.22986.
  266. Соколов С.Ф., Бомонина Е.В. Сравнительная эффективность и безопасность аллапинина, этацизина и амиодарона и выбор оптимальной антиаритмической терапии по контролю ритма при пароксизмальной мерцательной аритмии. Кардиология: новости, мнения, обучение. 2015;3(6):65-75.
  267. N. M. Lapointe, d. Dai, l. Thomas et al. Antiarrhythmic drug use in patients <65 years of age with atrial fibrillation and without structural heart disease. Am j cardiol. 2015; 115(3): 316–322
  268. Сычев О.С., Романова Е.Н., Срибная О.В. Результаты клинического исследования «оценка эффективности и безопасности препарата этацизина у больных с нарушениями ритма без выраженной органической патологии сердца». Аритмологія". 2016; 3(19):3-10
  269. X.Gao, A.Guha, B.Buck et al. Initiation and outcomes with Class Ic antiarrhythmic drug therapy. Indian Pacing Electrophysiol J. 2018 Mar-Apr; 18(2): 68–72.].
  270. Emdin CA, Callender T, Cao J, Rahimi K. Effect of antihypertensive agents on risk of atrial fibrillation: a meta-analysis of large-scale randomized trials. Europace 2015;17:701–10;
  271. Lip GY, Frison L, Grind M. Angiotensin converting enzyme inhibitor and angiotensin receptor blockade use in relation to outcomes in anticoagulated patients with atrial fibrillation. J Intern Med 2007;261:577–86;
  272. The GISSI-AF Investigators. Valsartan for prevention of recurrent atrial fibrillation. N Engl J Med 2009;360:1606–17
  273. Haverkamp W, Breithardt G, Camm AJ et al. The potential for QT prolongation and pro-arrhythmia by non-anti-arrhythmic drugs: clinical and regulatory implications. Report on a Policy Conference of the European Society of Cardiology. Cardiovasc Res. 2000;47:219–233.
  274. Kääb S1, Hinterseer M, Näbauer M, Steinbeck G. Sotalol testing unmasks altered repolarization in patients with suspected acquired long-QT-syndrome-a case-control pilot study using i.v. sotalol. Eur Heart J. 2003;24:649–657.
  275. Fabritz L, Kirchhof P. Predictable and less predictable unwanted cardiac drugs effects: individual pre-disposition and transient precipitating factors. Basic Clin Pharmacol Toxicol. 2010;106:263– 268.
  276. Choy AM, Darbar D, Dell’Orto S et al. Exaggerated QT prolongation after cardioversion of atrial fibrillation. J Am Coll Cardiol 1999;34:396–401.
  277. Kirchhof P, Franz MR, Bardai A et al. Giant T-U waves precede torsades de pointes in long QT syndrome: a systematic electrocardiographic analysis in patients with acquired and congenital QT prolongation. J Am Coll Cardiol. 2009;54:143–149.
  278. Olsson LG, Swedberg K, Ducharme A et al. Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction: results from the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) program. J Am Coll Cardiol.
  279. Schneider MP, Hua TA, Bohm M et al. Prevention of atrial fibrillation by Renin-Angiotensin system inhibition a meta-analysis. J Am Coll Cardiol.
  280. Healey JS, Baranchuk A, Crystal E et al. Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis. J Am Coll Cardiol. 2005;45:1832–1839.
  281. Ducharme A, Swedberg K, Pfeffer MA et al. Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. Am Heart J. 2006;152:86–92.
  282. Anand K, Mooss AN, Hee TT et al. Meta-analysis: inhibition of renin-angiotensin system prevents new-onset atrial fibrillation. Am Heart J. 2006;152:217–222.
  283. Schmieder RE, Kjeldsen SE, Julius S et al. Reduced incidence of new-onset atrial fibrillation with angiotensin II receptor blockade: the VALUE trial. J Hypertens. 2008;26:403–411.
  284. Jibrini MB, Molnar J, Arora RR. Prevention of atrial fibrillation by way of abrogation of the renin- angiotensin system: a systematic review and meta-analysis. Am J Ther. 2008;15:36–43.
  285. Wachtell K, Lehto M, Gerdts E et al. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. J Am Coll Cardiol. 2005;45:712–719.
  286. Okin PM, Wachtell K, Devereux RB et al. Regression of electrocardiographic left ventricular hypertrophy and decreased incidence of newonset atrial fibrillation in patients with hypertension. JAMA. 2006;296:1242–1248.
  287. Goette A, Schon N, Kirchhof P et al. Angiotensin II-antagonist in paroxysmal atrial fibrillation (ANTIPAF) trial. Circ Arrhythm Electrophysiol. 2012;5:43–51.
  288. Yamashita T, Inoue H, Okumura K et al. RHYTHM II Investigators. Randomized trial of angiotensin II-receptor blocker vs. dihydropiridine calcium channel blocker in the treatment of paroxysmal atrial fibrillation with hypertension (J-RHYTHM II study). Europace. 2011;13:473– 479.
  289. Cosedis NJ, Johannessen A, Raatikainen P et al. Radiofrequency ablationas initial therapy in paroxysmal atrial fibrillation. N Engl J Med. 2012;367:1587–1595.
  290. Arbelo E, Brugada J, Hindricks G et al. Atrial Fibrillation Ablation Pilot Study Investigators. The atrial fibrillation ablation pilot study: a European Survey on Methodology and results of catheter ablation for atrial fibrillation conducted by the European Heart Rhythm Association. Eur Heart J. 2014;35:1466–1478.
  291. Calkins H, Reynolds MR, Spector P et al. Treatment of atrial fibrillation with antiarrhythmic drugs or radiofrequency ablation: two systematic literature reviews and meta-analyses. Circ Arrhythm Electrophysiol. 2009;2:349–361.
  292. Cappato R, Calkins H, Chen SA et al. Updated worldwide survey on the methods, efficacy, and safety of catheter ablation for human atrial fibrillation. Circ Arrhythm Electrophysiol. 2010;3:32–38.
  293. Kimura M, Sasaki S, Owada S et al. Comparison of lesion formation between contact force- guided and non-guided circumferential pulmonary vein isolation: a prospective, randomized study. Heart Rhythm, 2014;11:984–91.
  294. Sohns C, Karim R, Harrison J et al. Quantitative magnetic resonance imaging analysis of the relationship between contact force and left atrial scar formation after catheter ablation of atrial fibrillation. J Cardiovasc Electrophysiol. 2014;25:138–45.
  295. Hunter RJ, Baker V, Finlay MC et al. Point-by-Point Radiofrequency Ablation Versus the Cryoballoon or a Novel Combined Approach: A Randomized Trial Comparing 3 Methods of Pulmonary Vein Isolation for Paroxysmal Atrial Fibrillation (The Cryo Versus RF Trial). J Cardiovasc Electrophysiol. 2015;26:1307–14.
  296. Fürnkranz A, Brugada J, Albenque JP et al. Rationale and Design of FIRE AND ICE: A multicenter randomized trial comparing efficacy and safety of pulmonary vein isolation using a cryoballoon versus radiofrequency ablation with 3D-reconstruction. J Cardiovasc Electrophysiol. 2014;25:1314–20.
  297. Cappato R, Marchlinski FE, Hohnloser SH et al. Uninterrupted rivaroxaban vs. uninterrupted vitamin K antagonists for catheter ablation in non-valvular atrial fibrillation. Eur Heart J. 2015;36:1805–1811.
  298. Calkins H, Willems S, Gerstenfeld EP. Uninterrupted Dabigatran versus Warfarin for Ablation in Atrial Fibrillation. N Engl J Med. 2017;376:1627–1636.
  299. Luigi DB, David C, Karl GH. «Rationale and design of AXAFA-AFNET 5: an investigator-initiated, randomized, open, blinded outcome assessment, multi-centre trial to comparing continuous apixaban to vitamin K antagonists in patients undergoing atrial fibrillation catheter ablation». Europace. 2017;19:132–138. doi:10.1093/europace/euw368.
  300. Vamos M, Cappato R, Marchlinski FE et al. Hohnloser Efficacy and safety of rivaroxaban compared with vitamin K antagonists for peri-procedural anticoagulation in catheter ablation of atrial fibrillation: a systematic review and meta-analysis. Europace. 2016;18:1787–1794.
  301. Hohnloser SH, Camm AJ. Safety and efficacy of dabigatran etexilate during catheter ablation of atrial fibrillation: a meta-analysis of the literature. Europace. 2013;15:1407–11. doi: 10.1093/europace/eut241.
  302. Calkins H1, Kuck KH, Cappato R et al. 2012 HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design. J Interv Card Electrophysiol. 2012; 33:171–257. doi: 10.1007/s10840–012–9672–7.
  303. Sticherling C, Marin F, Birnie D et al. Antithrombotic management in patients undergoing electrophysiological procedures: a European Heart Rhythm Association (EHRA) position document endorsed by the ESC Working Group Thrombosis, Heart Rhythm Society (HRS), and Asia Pacific Heart Rhythm Society (APHRS). Europace. 2015;17:1197–214.
  304. Jones DG, HaldarSK, Hussain W et al. A randomized trial to assess catheter ablation versus rate control in the management of persistent atrial fibrillation in heart failure. J Am Coll Cardiol. 2013;61:1894–1903.
  305. Anselmino M, Matta M, D’Ascenzo F et al. Catheter ablation of atrial fibrillation in patients with left ventricular systolic dysfunction: a systematic review and meta-analysis. Circ Arrhythm Electrophysiol. 2014;7:1011–1018.
  306. Ganesan AN, Nandal S, Luker J et al. Catheter ablation of atrial fibrillation in patients with concomitant left ventricular impairment: a systematic review of efficacy and effect on ejection fraction. Heart Lung Circ. 2015;24:270–280.
  307. Khan MN, Jais P, Cummings J et al. PABA-CHF Investigators. Pulmonary-vein isolation for atrial fibrillation in patients with heart failure. N Engl J Med. 2008;359:1778–1785.
  308. Al Halabi S, Qintar M, Hussein A et al. Catheter Ablation for Atrial Fibrillation in Heart Failure Patients: A Meta-Analysis of Randomized Controlled Trials. JACC Clin Electrophysiol. 2015;1:200–209.
  309. Di Biase L, Mohanty P, Mohanty S et al. Ablation vs. Amiodarone for Treatment of Persistent Atrial Fibrillation in Patients With Congestive Heart Failure and an Implanted Device: Results From the AATAC Multicenter Randomized Trial. Circulation. 2016;134:e1989–90. doi:10.1161/CIRCULATIONAHA.115.019406.
  310. Hunter RJ, Berriman TJ, Diab I et al. A randomized controlled trial of catheter ablationversus medical treatment of atrial fibrillation in heart failure (the CAMTAFtrial). Circ Arrhythm Electrophysiol. 2014;7:31–38.
  311. MacDonald MR, Connelly DT, Hawkins NM et al. Radiofrequencyablation for persistent atrial fibrillation in patients with advanced heart failure andsevere left ventricular systolic
  312. Stulak JM, Dearani JA, Daly RC et al. Left ventriculardysfunction in atrial fibrillation: restoration of sinus rhythm by the Cox-maze proceduresignificantly improves systolic function and functional status. Ann Thorac Surg. 2006;82:494–501. 2006;47:1997–2004. 2010;55:2299–2307. doi: 10.1056/NEJMoa1701005. dysfunction: a randomised controlled trial. Heart. 2011;97:740–747
  313. Chen YW, Bai R, Lin T et al. Pacing or ablation: which is better for paroxysmal atrial fibrillation- related tachycardia-bradycardia syndrome? Pacing Clin Electrophysiol. 2014;37:403–411.
  314. Khaykin Y, Marrouche NF, Martin DO et al. Pulmonary vein isolation for atrial fibrillation in patients with symptomatic sinus bradycardia or pauses. J Cardiovasc Electrophysiol. 2004;15:784–789.
  315. Manolis AS, Dragazis I, Kapelakis I et al. Transesophageal overdrive pacing: A simple and versatile tool. Hosp Chronicles 2013;8: 143–145. Poulidakis E, Manolis AS. Transvenous temporary cardiac pacing. Rhythmos 2014; 9:20–27.
  316. Spector P, Reynolds MR, Calkins H et al. Meta-analysis of ablation of atrial flutter and supraventricular tachycardia. Am J Cardiol. 2009;104:671–677.
  317. Schmieder S, Ndrepepa G, Dong J et al. Acute and long-term results of radiofrequency ablation of common atrial flutter and the influence of the right atrial isthmus ablation on the occurrence of atrial fibrillation. Eur Heart J. 2003;24:956–962.
  318. Bandini A, Golia P, Caroli E et al. Atrial fibrillation after typical atrial flutter ablation: a long-term follow-up. J Cardiovasc Med (Hagerstown). 2011;12:110–115.
  319. Dewland TA, Glidden DV, Marcus GM. Healthcare utilization and clinical outcomes after catheter ablation of atrial flutter. PLoS One. 2014;9:e100509.
  320. Boersma LV, Castella M, van Boven W et al.. Atrial fibrillation catheter ablation versus surgical ablation treatment (FAST): a 2-center randomized clinical trial. Circulation. 2012;125:23–30.
  321. Verma A, Jiang CY, Betts TR et al. STAR AF II Investigators. Approaches to catheter ablation for persistent atrial fibrillation. N Engl J Med. 2015;372:1812–1822.
  322. Rohla M, Weiss TW, Pecen L, et al. Risk factors for thromboembolic and bleeding events in anticoagulated patients with atrial fibrillation: the prospective, multicentre observational PREvention oF thromboembolic events - European Registry in Atrial Fibrillation (PREFER in AF) BMJ Open 2019;9:e022478. doi: 10.1136/bmjopen-2018-022478
  323. Weimar T, Schena S, Bailey MS et al. The cox-maze procedure for lone atrial fibrillation: a single-center experience over 2 decades. Circ Arrhythm Electrophysiol. 2012;5:8–14.
  324. Huffman MD, Karmali KN, Berendsen MA et al. Concomitant atrial fibrillation surgery for people undergoing cardiac surgery. Cochrane Database of Systematic Reviews. 2016;8:CD011814. doi: 10.1002/14651858.CD011814.pub2.
  325. Krul SP, Driessen AH, van Boven WJ et al. Thoracoscopic video-assisted pulmonary vein antrum isolation, ganglionated plexus ablation, and periprocedural confirmation of ablation lesions: first results of a hybrid surgical-electrophysiological approach for atrial fibrillation. Circ Arrhythm Electrophysiol. 2011;4:262–270.
  326. Wang JG, Xin M, Han J et al. Ablation in selective patients with long-standing persistent atrial fibrillation: medium-term results of the Dallas lesion set. Eur J Cardiothorac Surg. 2014;46:213– 220.
  327. La Meir M, Gelsomino S, Luca F et al. Minimally invasive surgical treatment of lone atrial fibrillation: early results of hybrid versus standard minimally invasive approach employing radiofrequency sources. Int J Cardiol. 2013;167:1469–1475.
  328. Lawrance CP, Henn MC, Miller JR et al. A minimally invasive Cox maze IV procedure is as effective as sternotomy while decreasing major morbidity and hospital stay. J Thorac Cardiovasc Surg. 2014;148:955–961; discussion 962–952.
  329. Budera P, Straka Z, Osmancik P et al. Comparison of cardiac surgery with left atrial surgical ablation vs. cardiac surgery without atrial ablation in patients with coronary and/or valvular heart disease plus atrial fibrillation: final results of the PRAGUE-12 randomized multicentre study. Eur Heart J. 2012;33:2644–2652.
  330. Gillinov AM, Gelijns AC, Parides MK et al. CTSN Investigators. Surgical ablation of atrial fibrillation during mitral-valve surgery. N Engl J Med. 2015;372:1399–1409.
  331. Blomstrom-Lundqvist C, Johansson B, Berglin E et al. A randomized double-blind study of epicardial left atrial cryoablation for permanent atrial fibrillation in patients undergoing mitral valve surgery: the SWEDish Multicentre Atrial Fibrillation study (SWEDMAF). Eur Heart J. 2007;28:2902–2908.
  332. Chevalier P, Leizorovicz A, Maureira P et al. Left atrial radiofrequency ablation during mitral valve surgery: a prospective randomized multicentre study (SAFIR). Arch Cardiovasc Dis. 2009;102:769–775.
  333. Cheng DC, Ad N, Martin J, Berglin EE et al. Surgical ablation for atrial fibrillation in cardiac surgery: a meta-analysis and systematic review. Innovations (Phila). 2010;5:84–96.
  334. Barnett SD, Ad N. Surgical ablation as treatment for the elimination of atrial fibrillation: a meta-analysis. J Thorac Cardiovasc Surg. 2006;131:1029–1035. Ad N, Henry L, Hunt S, Holmes SD. Do we increase the operative risk by adding the Cox Maze III procedure to aortic valve replacement and coronary artery bypasssurgery? J Thorac Cardiovasc Surg. 2012;143:936–944.
  335. Arsenault KA, Yusuf AM, Crystal E et al. Interventions for preventing post-operative atrial fibrillation in patients undergoing heart surgery. Cochrane Database Syst Rev. 2013;1:Cd003611.
  336. Mathew JP, Fontes ML, Tudor IC et al. A multicenter risk index for atrial fibrillation after cardiac surgery. JAMA. 2004;291:1720–1729.
  337. Zhu J, Wang C, Gao D et al. Meta-analysis of amiodarone versus beta-blocker as a prophylactic therapy against atrial fibrillation following cardiac surgery. Intern Med J. 2012;42:1078–1087.
  338. Gillinov AM, Bagiella E, Moskowitz AJ et al. CTSN. Rate Control versus Rhythm Control for Atrial Fibrillation after Cardiac Surgery. N Engl J Med. 2016;374:1911–1921.
  339. Healey JS, Crystal E, Lamy A et al. Left Atrial Appendage Occlusion Study (LAAOS): results of a randomized controlled pilot study of left atrial appendage occlusion during coronary bypass surgery in patients at risk for stroke. Am Heart J. 2005;150:288–293.
  340. Tsai YC, Phan K, Munkholm-Larsen S et al. Surgical left atrial appendage occlusion during cardiac surgery for patients with atrial fibrillation: a meta-analysis. Eur J Cardiothorac Surg. 2015;47:847–854.
  341. Weerasooriya R, Davis M, Powell A et al. The Australian intervention randomized control of rate in atrialfi brillation trial (AIRCRAFT). J Am Coll Cardiol. 2003;41:1697–1702.
  342. Wood MA, Brown-Mahoney C, Kay GN, Ellenbogen KA. Clinical outcomes after ablation and pacing therapy for atrial fibrillation: a meta-analysis. Circulation. 2000;101:1138–1144.
  343. Gasparini M, Auricchio A, Metra M et al. Long-term survival in patients undergoing cardiac resynchronization therapy: the importance of performing atrio-ventricular junction ablation in patients with permanent atrial fibrillation. Eur Heart J. 2008;29:1644–1652.
  344. Upadhyay GA, Choudhry NK, Auricchio A et al. Cardiac resynchronization in patients with atrial fibrillation: a meta-analysis of prospective cohort studies. J Am Coll Cardiol. 2008;52:1239– 1246.
  345. Auricchio A, Metra M, Gasparini M et al. Long-term survival of patients with heart failure and ventricular conduction delay treated with cardiac resynchronization therapy. Am J Cardiol. 2007;99:232–238.
  346. Dong K, Shen WK, Powell BD et al. Atrioventricular nodal ablation predicts survival benefit in patients with atrial fibrillation receiving cardiac resynchronization therapy. Heart Rhythm. 2010;9:1240–5.
  347. Di Biase L, Lakkireddy D, Trivedi C et al. Feasibility and safety of uninterrupted periprocedural apixaban administration in patients undergoing radiofrequency catheter ablation for atrial fibrillation: results from a multicenter study. Heart Rhythm. 2015;12:1162–8.
  348. Santangeli P, Di Biase L, Horton R et al. Ablation of atrial fibrillation under therapeutic warfarin reduces periprocedural complications: evidence from a meta-analysis. Circ Arrhythm Electrophysiol. 2012;5:302–11.
  349. Di Biase L, Burkhardt JD, Mohanty P et al. Periprocedural stroke and management of major bleeding complications in patients undergoing catheter ablation of atrial fibrillation: the impact of periprocedural therapeutic international normalized ratio. Circulation. 2010;121:2550–6.
  350. Wazni OM, Beheiry S, Fahmy T et al. Atrial fibrillation ablation in patients with therapeutic international normalized ratio: comparison of strategies of anticoagulation management in the periprocedural period. Circulation. 2007;116:2531–4.
  351. Schmidt M, Segerson NM, Marschang H et al. Atrial fibrillation ablation in patients with therapeutic international normalized ratios. Pacing Clin Electrophysiol. 2009;32:995–9.
  352. Hakalahti A, Uusimaa P, Ylitalo K, Raatikainen MJ. Catheter ablation of atrial fibrillation in patients with therapeutic oral anticoagulation treatment. Europace. 2011;13:640–5.
  353. Calkins H, Gerstenfeld EP, Schilling R et al. RE-CIRCUIT study-randomized evaluation of Dabigatran etexilate compared to warfarin in pulmonary vein ablation: assessment of an uninterrupted periprocedural anticoagulation strategy. Am J Cardiol. 2015;115:154–5.
  354. Bassiouny M, Saliba W, Rickard J et al. Use of dabigatran for periprocedural anticoagulation in patients undergoing catheter ablation for atrial fibrillation. Circ Arrhythm Electrophysiol. 2013;6:460–6.
  355. Bin Abdulhak AA, Khan AR, Tleyjeh IM et al. Safety and efficacy of interrupted dabigatran for peri-procedural anticoagulation in catheter ablation of atrial fibrillation: a systematic review and meta-analysis. Europace. 2013;15:1412–20.
  356. Providência R, Marijon E, Albenque JP et al. Rivaroxaban and dabigatran in patients undergoing catheter ablation of atrial fibrillation. Europace. 2014;16:1137–44.
  357. Winkle RA, Mead RH, Engel G et al. Peri-procedural interrupted oral anticoagulation for atrial fibrillation ablation: comparison of aspirin, warfarin, dabigatran, and rivaroxaban. Europace, 2014;16:1443–9.
  358. Armbruster HL, Lindsley JP, Moranville MP et al., Safety of novel oral anticoagulants compared with uninterrupted warfarin forcatheter ablation of atrial fibrillation. Ann Pharmacother, 2015;49:278–84.
  359. Ren JF, Marchlinski FE and Callans DJ. Left atrial thrombus associated with ablation for atrial fibrillation: identification with intracardiac echocardiography. J Am Coll Cardiol. 2004;43:1861– 7.
  360. Saksena S, Sra J, Jordaens L et al. A prospective comparison of cardiac imaging using intracardiac echocardiography with transesophageal echocardiography in patients with atrial fibrillation: the intracardiac echocardiography guided cardioversion helps interventional procedures study. Circ Arrhythm Electrophysiol. 2010;3:571–7.
  361. Baran J, Stec S, Pilichowska-Paszkiet E et al. Intracardiac echocardiography for detection of thrombus in the left atrial appendage: comparison with transesophageal echocardiography in patients undergoing ablation for atrial fibrillation: the Action-Ice I Study. Circ Arrhythm Electrophysiol. 2013;6:1074–81.
  362. Ren JF, Marchlinski FE, Supple GE et al. Intracardiac echocardiographic diagnosis of thrombus formation in the left atrial appendage: a complementary role to transesophageal echocardiography. Echocardiography. 2013;30:72–80.
  363. Anter E, Silverstein J, Tschabrunn CM et al. Comparison of intracardiac echocardiography and transesophageal echocardiography for imaging of the right and left atrial appendages. Heart Rhythm, 2014;11:1890–7.
  364. Sriram CS, Banchs JE, Moukabary T et al. Detection of left atrial thrombus by intracardiac echocardiography in patients undergoing ablation of atrial fibrillation. J Interv Card Electrophysiol, 2015;43:227–36,1861–7.
  365. Olga Lazoura, Tevfik F. Ismail Christopher Pavitt, Alistair Lindsay, Mona Sriharan, Michael Rubens, Simon Padley, Alison Duncan, Tom Wong, Edward Nicol. A low-dose, dual-phase cardiovascular CT protocol to assess left atrial appendage anatomy and exclude thrombus prior to left atrial intervention. Int J Cardiovasc Imaging. 2016;32:347–354.
  366. Zou H, Zhang Y, Tong J, Liu Z. Multidetector computed tomography for detecting left atrial/left atrial appendage thrombus: a meta-analysis. Intern Med J. 2015;35: 1044–53.
  367. Maleki K, Mohammadi R, Hart D et al. Intracardiac ultrasound detection of thrombus on transseptal sheath: incidence, treatment, and prevention. J Cardiovasc Electrophysiol. 2005;16: 561–5.
  368. Wazni OM, Rossillo A, Marrouche NF et al. Embolic events and char formation during pulmonary vein isolation in patients with atrial fibrillation: impact of different anticoagulation regimens and importance of intracardiac echo imaging. J Cardiovasc Electrophysiol. 2005;16:576–81.
  369. Shah, D. Filamentous thrombi during left-sided sheath-assisted catheter ablations. Europace. 2010;12:1657–8.
  370. Ren JF, Marchlinski FE, Callans DJ et al. Increased intensity of anticoagulation may reduce risk of thrombus during atrial fibrillation ablation procedures in patients with spontaneous echo contrast. J Cardiovasc Electrophysiol. 2005;16:474–7.
  371. Bruce CJ, Friedman PA, Narayan O et al. Early heparinization decreases the incidence of left atrial thrombi detected by intracardiac echocardiography during radiofrequency ablation for atrial fibrillation. J Interv Card Electrophysiol. 2008;22:211–9.
  372. Asbach S, Biermann J, Bode C, Faber TS. Early Heparin Administration Reduces Risk for Left Atrial Thrombus Formation during Atrial Fibrillation Ablation Procedures. Cardiol Res Pract. 2011;2011:615087.
  373. Briceno DF, Villablanca PA, Lupercio F et al. Clinical Impact of Heparin Kinetics During Catheter Ablation of Atrial Fibrillation: Meta-Analysis and Meta-Regression. J Cardiovasc Electrophysiol, 2016;27: 683–93.
  374. Chilukuri K, Henrikson CA, Dalal D et al. Incidence and outcomes of protamine reactions in patients undergoing catheter ablation of atrial fibrillation. J Interv Card Electrophysiol. 2009;25(3):175-81.
  375. Calkins H, Brugada J, Packer DL et al. HRS/EHRA/ECAS expert Consensus Statement on catheter and surgical ablation of atrial fibrillation: recommendations for personnel, policy, procedures and follow-up. A report of the Heart Rhythm Society (HRS) Task Force on catheter and surgical ablation of atrial fibrillation. Heart Rhythm, 2007;4:816–61.
  376. Calkins H, Hindricks G, Cappato R et al. 2017 HRS/EHRA/ECAS/APHRS/ SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation:
  377. Holmes DR Jr, Kar S, Price MJ et al. Prospective randomized evaluation of the Watchman Left Atrial Appendage Closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial. J Am Coll Cardiol. 2014;64:1–12.
  378. Holmes DR, Reddy VY, Turi ZG et al. Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised noninferiority trial. Lancet. 2009;374:534–542.
  379. Reddy VY, Doshi SK, Sievert H et al. Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Followup of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial. Circulation. 2013;127:720–729.
  380. Reddy VY, Mobius-Winkler S, Miller MA et al. Left atrial appendage closure with the Watchman device in patients with a contraindication for oral anticoagulation: the ASAP study (ASA Plavix Feasibility Study With Watchman Left Atrial Appendage Closure Technology). J Am Coll Cardiol. 2013;61:2551–2556.
  381. Santoro G, Meucci F, Stolcova M et al. Percutaneous left atrial appendage occlusion in patients with non-valvular atrial fibrillation: implantation and up to four years follow-up of the AMPLATZER Cardiac Plug. EuroIntervention. 2016;11:1188–1194.
  382. Tzikas A, Shakir S, Gafoor S et al. Left atrial appendage occlusion for stroke prevention in atrial fibrillation: multicentre experience with the AMPLATZER Cardiac Plug. EuroIntervention. 2016;11:1170–9.
  383. Reddy VY, Sievert H, Halperin J et al. PROTECT AF Steering Committee and Investigators. Percutaneous left atrial appendage closure vs warfarin for atrial fibrillation: a randomized clinical trial. JAMA. 2014;312:1988–1998.
  384. Holmes DR Jr, Doshi SK, Kar S et al. Left Atrial Appendage Closure as an Alternative toWarfarin for Stroke Prevention in Atrial Fibrillation: A Patient-Level Meta-Analysis. J Am Coll Cardiol. 2015;65:2614–2623.
  385. Boersma LV, Schmidt B, Betts TR et al. Implant success and safety of left atrial appendage closure with the WATCHMAN device: peri-procedural outcomes from the EWOLUTION registry. Eur Heart J. 2016;37:2465–74.
  386. Kleinecke C, Park JW, Gödde M et al. Twelve-month follow-up of left atrial appendage occlusion with Amplatzer Amulet. Cardiol J. 2017;24:131–8.
  387. Friedman DJ, Piccini JP, Wang T et al. Association between left atrial appendage occlusion and readmission for thromboembolism among patients with atrial fibrillation undergoing concomitant cardiac surgery. JAMA. 2018;319:365–74.
  388. Van Laar C, Verberkmoes NJ, van Es HW et al. Thoracoscopic Left Atrial Appendage Clipping: A Multicenter Cohort Analysis. JACC Clin Electrophysiol. 2018;4:893–901.
  389. Manolis AJ, Rosei EA, Coca A et al. Hypertensionand atrial fibrillation: diagnostic approach, prevention and treatment. Position paperof the Working Group «Hypertension Arrhythmias and Thrombosis» of the European Society of Hypertension. J Hypertens. 2012;30:239–252.
  390. Marott SC, Nielsen SF, Benn M, Nordestgaard BG. Antihypertensive treatmentand risk of atrial fibrillation: a nationwide study. Eur Heart J. 2014;35:1205–1214.
  391. Madrid AH, BuenoMG, RebolloJM et al. Use of irbesartan to maintains in us rhythm in patients with long-lasting persistent atrial fibrillation: a prospective and randomized study. Circulation. 2002;106:331–336.
  392. Ueng K-C, Tsai T-P, Yu W-C et al. Use of enalapril to facilitate sinus rhythm maintenance afterexternal cardioversion of long-standing persistent atrial fibrillation. Results of aprospective and controlled study. Eur Heart J. 2003;24:2090–2098.
  393. Tveit A, Seljeflot I, Grundvold I et al. Effect of candesartanand various inflammatory markers on maintenance of sinus rhythm after electrical cardioversion for atrial fibrillation. Am J Cardiol. 2007;99:1544–154.
  394. Antz M, Weiss C, Volkmer M et al. Risk of suddendeath after successful accessory atrioventricular pathway ablation in resuscitatedpatients with Wolff – Parkinson – White syndrome. J Cardiovasc Electrophysiol. 2002;13:231–236.
  395. Timmermans C, Smeets JL, Rodriguez LM et al. Aborted sudden death in the Wolff – Parkinson – White syndrome. Am J Cardiol. 1995;76:492–494.
  396. Bromberg BI, Lindsay BD, Cain ME, Cox JL. Impact of clinical history and electrophysiologiccharacterization of accessory pathways on management strategies toreduce sudden death among children with Wolff – Parkinson – White syndrome. J Am Coll Cardiol. 1996;27:690–695.
  397. Blomstrom-Lundqvist C, Scheinman MM, Aliot EM et al. European Society of Cardiology Committee, NASPE – Heart Rhythm Society. ACC/AHA/ESC guidelines for the management of patients with supraventricular arrhythmias–executive summary. a report of the American college of cardiology/American heart association task force on practice guidelines and the
  398. Pappone C, Santinelli V, Manguso F et al. A randomized study of prophylactic catheter ablation in asymptomatic patients with the Wolff – Parkinson – White syndrome. N Engl J Med. 2003;349:1803–1811.
  399. Boahene KA, Klein GJ, Yee R et al. Termination of acute atrial fibrillation in the Wolff – Parkinson – White syndrome by procainamide and propafenone: importance of atrial fibrillatory cycle length. J Am Coll Cardiol. 1990;16:1408–1414.
  400. Ludmer PL, McGowan NE, Antman EM, Friedman PL. Efficacy of propafenone in Wolff – Parkinson – White syndrome: electrophysiologic findings and long-term follow-up. J Am Coll Cardiol. 1987;9:1357–1363.
  401. Olivotto I, Cecchi F, Casey SA et al. Impact of atrial fibrillation on the clinical course of hypertrophic cardiomyopathy. Circulation. 2001;104:2517–2524.
  402. Elliott PM, Anastasakis A, Borger MA et al. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force forthe Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J. 2014;35:2733–2779.
  403. Maron BJ, Ommen SR, Semsarian C et al. Hypertrophic cardiomyopathy: present and future, with translation into contemporary cardiovascular medicine. J Am Coll Cardiol. 2014;64:83–99.
  404. Robinson K, Frenneaux MP, Stockins B et al. Atrial fibrillation in hypertrophic cardiomyopathy: a longitudinal study. J Am Coll Cardiol. 1990;15:1279–1285.
  405. Kaufman ES. Mechanisms and clinical management of inherited channelopathies: long QT syndrome, Brugada syndrome, catecholaminergic polymorphic ventricular tachycardia, and short QT syndrome. Heart Rhythm. 2009;6:S51–55.
  406. Kusunose K, Yamada H, Nishio S et al. Clinical utility of single-beat E/e’ obtained by simultaneous recording off lowand tissue Doppler velocities in atrial fibrillation with preserved systolic function. JACC Cardiovasc Imaging 2009;2:1147–1156.
  407. Li C, Zhang J, Zhou C et al. Will simultaneous measurement of E/e’ index facilitate the non-invasive assessment of left ventricular filling pressurein patients with non-valvular atrial fibrillation? Eur J Echocardiogr. 2010;11:296–301.
  408. Senechal M, O’Connor K, Deblois J et al. A simple Doppler echocardiography method to evaluate pulmonary capillary wedge pressure in patients with atrial fibrillation. Echocardiography. 2008;25:57–63.
  409. Sohn DW, Song JM, Zo JH et al. Mitral annulus velocity in the evaluation of left ventricular diastolic function in atrial fibrillation. J Am Soc Echocardiogr. 1999;12:927–931.
  410. Wada Y, Murata K, Tanaka T et al. Simultaneous Doppler tracing of transmitral inflow and mitral annular velocity as an estimate of elevated left ventricular filling pressure in patients with atrial fibrillation. Circ J. 2012;76:675–681.
  411. Ponikowski P, Voors AA, Anker SD et al. The Task Force for the diagnosis andteatment of acute and chronic heart failure of the European Society of Cardiology (ESC). 2016 ESC Guidelines for the diagnosis and treatment of acute and chronicheart failure. Eur Heart J. 2016;37:2129–2200. doi: 10.1093/eurheartj/ehw128.
  412. Kelly JP, Mentz RJ, Mebazaa A et al. Patient selection in heart failure with preservedejection fraction clinical trials. J Am Coll Cardiol. 2015;65:1668–1682.
  413. Disertori M, Latini R, Barlera S et al. GISSI-AF Investigators Valsartan for prevention of recurrent atrial fibrillation. N Engl J Med 2009;360:1606–1617.
  414. Yusuf S, Healey JS, Pogue J et al. Active I Investigators Irbesartan in patients with atrial fibrillation. N Engl J Med. 2011;364:928–938.
  415. McMurray JJ, Packer M, Desai AS et al. PARADIGM-HF Investigators andCommittees. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371:993– 1004.
  416. Kotecha D, Holmes J, Krum Het al. Beta-Blockers in Heart Failure CollaborativeGroup. Efficacy of beta blockers in patients with heart failure plus atrial fibrillation:an individual-patient data meta-analysis. Lancet. 2014;384:2235–2243.
  417. Swedberg K, Zannad F, McMurray JJ et al. Eplerenone and atrial fibrillation in mild systolic heart failure: results fromthe EMPHASIS-HF (Eplerenone in Mild Patients Hospitalization And SurvIvalStudy in Heart Failure) study. J Am Coll Cardiol. 2012;59:1598–1603.
  418. Chiang CE, Naditch-Brule L, Murin J et al. Distribution and risk profile of paroxysmal, persistent, and permanent atrial fibrillation in routine clinical practice: insight from the reallife global survey evaluating patients with atrial fibrillation international registry. Circ Arrhythm Electrophysiol. 2012;5:632–639.
  419. Wang TJ, Larson MG, Levy D et al. Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: the Framingham Heart Study. Circulation. 2003;107:2920–2925.
  420. Kishore A, Vail A, Majid A et al. Detection of atrial fibrillation after ischemic stroke or transient ischemic attack: a systematic review and meta-analysis. Stroke. 2014;45:520–526.
  421. Schnabel RB, Yin X, Gona P et al. 50 year trends in atrial fibrillation prevalence, incidence, risk factors, and mortality in the Framingham Heart Study: a cohort study. Lancet. 2015;386:154– 162.
  422. Benjamin EJ, Wolf PA, D’Agostino RB et al. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation. 1998;98:946–952.
  423. Stewart S, Hart CL, Hole DJ, McMurray JJ. A population-based study of the longterm risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study. Am J Med. 2002;113:359–364.
  424. Andersson T, Magnuson A, Bryngelsson IL, Frobert O, Henriksson KM, Edvardsson N, Poci D. All- cause mortality in 272 186 patients hospitalized with incident atrial fibrillation 1995–2008: a Swedish nationwide long-term casecontrol study. Eur Heart J. 2013;34:1061–1067.
  425. Hijazi Z, Lindback J, Alexander JH et al. ARISTOTLE and STABILITY Investigators. The ABC (age, biomarkers, clinical history) stroke risk score: a biomarker-based risk score for predicting stroke in atrial fibrillation.Eur Heart J. 2016;37:1582–1590.
  426. Mant J, Hobbs FD, Fletcher K et al. BAFTA investigators, Midland Research Practices Network (MidReC).Warfarin versus aspirinfor stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): arandomised controlled trial. Lancet. 2007;370:493–503.
  427. Ruff CT, Giugliano RP, Braunwald E et al. Comparisonof the efficacy and safety of new oral anticoagulants with warfarin in patientswith atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014;383:955–962.
  428. Marinigh R, Lip GY, Fiotti N et al. Age as a risk factor for strokein atrial fibrillation patients: implications for thromboprophylaxis. J Am Coll Cardiol. 2010;56:827–837.
  429. Kotecha D, Chudasama R, Lane DA et al.Atrial fibrillation and heart failure due to reduced versus preserved ejection fraction: A systematic reviewand meta-analysis of death and adverse outcomes. Int J Cardiol. 2016;203:660–666.
  430. Gage BF, Boechler M, Doggette AL et al. Adverse outcomes and predictors of underuse of antithrombotic therapy inmedicare beneficiaries with chronic atrial fibrillation. Stroke. 2000;31:822–827.
  431. Andreotti F, Rocca B, Husted S et al. ESC Thrombosis Working Group. Antithrombotic therapy in the elderly: expert positionpaper of the European Society of Cardiology Working Group on Thrombosis.Eur Heart J. 2015;36:3238–3249.
  432. Bates SM, Greer IA, Middeldorp S et al. VTE, thrombophilia, antithrombotic therapy, and pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141:e691S–736S.
  433. Aizer A, Gaziano JM, Cook NR et al. Relation of vigorousexercise to risk of atrial fibrillation. Am J Cardiol. 2009;103:1572–1577.
  434. Mozaffarian D, Furberg CD, Psaty BM, Siscovick D. Physical activity and incidenceof atrial fibrillation in older adults: the cardiovascular health study. Circulation. 2008;118:800–807.
  435. Mont L, Sambola A, Brugada J et al. Long-lasting sport practice and lone atrial fibrillation. Eur Heart J. 2002;23:477–482.
  436. Abdulla J, Nielsen JR. Is the risk of atrial fibrillation higher in athletes than in thegeneral population? A systematic review and meta-analysis. Europace. 2009;11:1156–1159.
  437. Thelle DS, Selmer R, Gjesdal K et al. Resting heart rate and physical activity as risk factors for lone atrial fibrillation: a prospective study of 309 540 men and women. Heart. 2013;99:1755– 1760.
  438. Andersen K, Farahmand B, Ahlbom Aet al. Risk of arrhythmias in 52 755 long-distance cross-country skiers: a cohort study. Eur Heart J. 2013;34:3624–3631.
  439. Karjalainen J, Kujala UM, Kaprio J et al. Lone atrial fibrillation invigorously exercising middle aged men: case-control study. BMJ. 1998;316:1784–1785.
  440. Calvo N, Mont L, Tamborero D et al. Efficacy of circumferential pulmonary vein ablation of atrialfibrillation in endurance athletes. Europace. 2010;12:30–36.
  441. Koopman P, Nuyens D, Garweg C et al. Efficacy of radiofrequency catheter ablation in athletes with atrial fibrillation. Europace. 2011; 13:1386–1393.
  442. Nagao K, Tsuchihashi K, Tanaka S, Iimura O. Studies on atrial arrhythmias in atrialseptal defect. The influences of aging on atrial fibrillation. Nihon Ronen Igakkai Zasshi. 1995;32:27–32.
  443. Giamberti A, Chessa M, Abella R et al. Surgical treatment of arrhythmias in adults with congenital heart defects. Int J Cardiol. 2008;129:37–41.
  444. Yamada T, McElderry HT, Muto M et al. Pulmonary vein isolationin patients with paroxysmal atrial fibrillation after direct suture closure of congenitalatrial septal defect. Circ J. 2007;71:1989–1992.
  445. Kobayashi J, Yamamoto F, Nakano K et al. Maze procedurefor atrial fibrillation associated with atrial septal defect. Circulation. 1998;98:II399–402.
  446. Shim H, Yang JH, Park PW et al. Efficacy of the maze procedure foratrial fibrillation associated with atrial septal defect. Korean J Thorac Cardiovasc Surg. 2013;46:98–103.
  447. Gutierrez SD, Earing MG, Singh AK et al. Atrial tachyarrhythmiasand the Cox-maze procedure in congenital heart disease. Congenit Heart Dis. 2013;8:434–439.
  448. Bockeria L Golukhova E Dadasheva M et al. Advantages and disadvantages of one-stage and two-stage surgery for arrhythmias and Ebstein’s anomaly. Eur J Cardiothorac Surg: 2005;28:536–540.
  449. Бокерия Л.А., Ревишвили А.Ш., Шмуль А.В. и др. Результаты хирургического лечения фибрилляции предсердий у пациентов с пороками сердца // Анналы аритмологии. – 2012. – № 4. – С. 14–22.
  450. Jensen AS, Idorn L, Norager B et al. Anticoagulation in adults with congenital heart disease: The who, the when and the how? Heart. 2014;101:424–429.
  451. Ammash NM, Phillips SD, Hodge DO et al. Outcome of direct current cardioversion for atrial arrhythmiasin adults with congenital heart disease. Int J Cardiol. 2012;154:270–274.
  452. Feltes TF, Friedman RA. Transesophageal echocardiographic detection of atrialthrombi in patients with nonfibrillation atrial tachyarrhythmias and congenital heart disease. J Am Coll Cardiol. 1994;24:1365–1370.
  453. Goldstone AB, Patrick WL, Cohen JE et al. Early surgicalintervention or watchful waiting for the management of asymptomatic mitral regurgitation: a systematic review and meta-analysis. Ann Cardiothorac Surg. 2015;4:220–229.
  454. Schoen T, Pradhan AD, Albert CM, Conen D. Type 2 diabetes mellitus and risk ofincident atrial fibrillation in women. J Am Coll Cardiol. 2012;60:1421–1428.
  455. Du X, Ninomiya T, de Galan B et al. Risks of cardiovascularevents and effects of routine blood pressure lowering among patients with type 2diabetes and atrial fibrillation: results of the ADVANCE study. Eur Heart J. 2009;30:1128–1135.
  456. Rizzo MR, Sasso FC, Marfella R et al. Autonomic dysfunction is associated with brief episodesof atrial fibrillation in type 2 diabetes. J Diabetes Complications. 2015;29:88–92.
  457. B.P Krijthe, J.Heeringa, J.A Kors et al. Serum Potassium Levels and the Risk of Atrial Fibrillation: The Rotterdam Study. Int J Cardiol 2013:168(6):5411-5.
  458. Kodama S, Saito K, Tanaka S, Horikawa C, Saito A, Heianza Y et al. . Alcohol consumption and risk of atrial fibrillation: a meta-analysis. J Am Coll Cardiol 2011;57:427–36
  459. Donath MY, Shoelson SE. Type 2 diabetes as an inflammatory disease. Nat Rev Immunol. 2011;11:98–107.
  460. Ziolo MT, Mohler PJ. Defining the role of oxidative stress in atrial fibrillation anddiabetes. J Cardiovasc Electrophysiol. 2015;26:223–225.
  461. Fatemi O, Yuriditsky E, Tsioufis C et al. Impact of intensive glycemic control on the incidence of atrial fibrillation and associated cardiovascular outcome sin patients with type 2 diabetes mellitus (from the Actionto Control Cardiovascular Riskin Diabetes Study). Am J Cardiol. 2014;114:1217–1222.
  462. Overvad TF, Skjoth F, Lip GY et al. Duration of Diabetes Mellitus and Risk of Thromboembolism and Bleeding in Atrial Fibrillation: Nationwide Cohort Study. Stroke. 2015;46:2168–2174.
  463. Chang S-H, Wu L-S, Chiou M-J et al. Association of metformin with lower atrial fibrillation risk among patients with type 2 diabetes mellitus: a population-based dynamic cohortand in vitro studies. Cardiovasc Diabetol. 2014;13:123.
  464. Vizzardi E, Sciatti E, Bonadei I et al. Obstructive sleep apnoea-hypopnoea and arrhythmias: new updates. J Cardiovasc Med. (Hagerstown). 2017;18:490–500.
  465. Frost L, Vestergaard P, Mose-kilde L. Hyperthyroidism and risk of atrial fibrillation or flutter. a population-based study. Arch Intern Med 2004;164:1675–8.
  466. Bitter T, Nolker G, Vogt J et al. Predictors of recurrencein patients undergoing cryoballoon ablation for treatment of atrial fibrillation:the independent role of sleep-disordered breathing. J Cardiovasc Electrophysiol. 2012;23:18–25.
  467. Ng CY, Liu T, Shehata M et al. Meta-analysis of obstructivesleep apnea as predictor of atrial fibrillation recurrence after catheter ablation. Am J Cardiol. 2011;108:47–51.
  468. Linz D. Atria lfibrillation in obstructive sleep apnea: atrial arrhythmogenic substrate of a different sort. Am J Cardiol. 2012;110:1071.
  469. Patel D, Mohanty P, Di Biase L et al. Safety andefficacy of pulmonary vein antral isolation in patients with obstructive sleep apnea: the impact of continuous positive airway pressure. Circ Arrhythm Electrophysiol. 2010;3:445–451.
  470. Kim EJ, Lyass A, Wang N, Massaro JM, Fox CS, Benjamin EJ et al. . Relation of hypothy-roidism and incident atrial fibril-lation (from the Framingham Heart Study). Am Heart J 2014;167:123– 6.Naruse Y, Tada H, Satoh M et al. Concomitant obstructive sleep apnea increases the recurrence of atrial fibrillation followingradiofrequency catheter ablation of atrial fibrillation: clinical impact of continuous positive airway pressure therapy. Heart Rhythm. 2013;10:331–337.
  471. Neilan TG, Farhad H, Dodson JA et al. Effect of sleep apnea and continuous positive airway pressure on cardiacstructure and recurrence of atrial fibrillation. J Am Heart Assoc. 2013;2:e000421.
  472. Hill NR, Fatoba ST, Oke JL et al. Global Prevalence of Chronic Kidney Disease – A Systematic Review and Meta-Analysis. PLoS One. 2016;11:e0158765.
  473. Benjamin AS, Sunghee K, Jonathan PP et al. Insights From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Registry. Circulation. 2013;128:721–728.
  474. Бойцов С.А., Лукьянов М.М., Якушин С.С. и др. Регистр кардиоваскулярных заболеваний (РЕКВАЗА): диагностика, сочетаннаясердечно-сосудистаяпатология, сопутствующие заболевания и лечение в условиях реальной амбулаторно-поликлинической практики. // Кардиоваскулярная терапия и профилактика. – 2014. – № 13. – С. 44–50.
  475. Bansal N, Zelnick LR, Alonso A et al. eGFR and albuminuria in relation to risk of incident atrial fibrillation: ameta-analysis of the Jackson Heart Study, theMulti-Ethnic Study of Atherosclerosis, and the Cardiovascular Health Study. Clin J Am Soc Nephrol. 2017;12:1386– 1398.
  476. Benjamin EJ, Blaha MJ, Chiuve SE et al. American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart Disease and Stroke Statistics-2017 Update: A Report From the American Heart Association. Circulation. 2017;135:e146-e603.
  477. Olesen JB, Lip GY, Kamper AL et al. Stroke and bleeding in atrial fibrillation with chronic kidney diseases. N Engl J Med. 2012;367:625–635.
  478. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31–41.
  479. Levey AS, Coresh J, Greene T et al. Chronic Kidney Disease Epidemiology Collaboration. Expressing the Modification of Diet in Renal Disease Study equation for estimating glomerular filtration rate with standardized serum creatinine values. Clin. Chem. 2007;53:766–772.
  480. Levey AS, Stevens LA, Schmid CH et al. CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150:604–612.
  481. Risom SS, Zwisler AD, Johansen PP et al. Exercise-based cardiac rehabilitation for adults with atrial fibrillation. Cochrane Database of Systematic Reviews. 2016;5:CD011197.
  482. Hegbom F, Sire S, Heldal M et al. Short-term exercise training in patients with chronic atrial fibrillation: effects on exercise capacity, AV conduction, and quality of life. Journal of Cardiopulmonary Rehabilitation. 2006;26:24–9.
  483. Malmo V, Nes BM, Amundsen BH et al. Aerobic interval training reduces the burden of atrial fibrillation in the short term: a randomized trial. Circulation. 2016;133:466–73.
  484. Osbak PS, Mourier M, Kjaer A et al. A randomized study of the effects of exercise training on patients with atrial fibrillation. American Heart Journal. 2011;162:1080–7.
  485. Bos D, Bano A, Hofman A, VanderWeele TJ, Kavousi M, Franco OH, Vernooij MW, Peeters RP, Ikram MA, Chaker L. Thyroid function and atrial fibrillation: Is there a mediating role for epicardial adipose tissue? Clinical Epidemiology, Volume 2018:10 Pages 225–234.
  486. Agata Bielecka-Dabrowa, Dimitri P Mikhailidis, Jacek Rysz and Maciej Banach. The mechanisms of atrial fibrillation in hyperthyroidism. Thyroid Research 2009, 2:4 doi:10.1186/1756-6614-2-4
  487. Risom SS, Zwisler AD, Rasmussen TB et al. Cardiac rehabilitation versus usual care for patients treated with catheter ablation for atrial fibrillation: results of the randomized CopenHeartRFA trial. American Heart Journal. 2016;181:120–9. Zeren M Demir R Yig it Z Gurses HN. Effects of ins piratory muscle training on pulmonary function, respiratory muscle strength and functional capacity in patients with atrial fibrillation: a randomized controlled trial. Clinical Rehabilitation. 2016;30:1165–74.
  488. Kato M, Kubo A, Nihei F et al. Effects of exercise training on exercise capacity, cardiac function, BMI, and quality of life in patients with atrial fibrillation: a meta-analysis of randomized-controlled trials. Int J Rehabil Res. 2017;40:193–201.
  489. Smart NA, King N, Lambert JD et al. Exercise-based cardiac rehabilitation improves exercise capacity and health-related quality of life in people with atrial fibrillation: a systematic review and meta-analysis of randomised and non-randomised trials. Open Heart. 2018;5:e000880.
  490. Luo N, Merrill P, Parikh KS et al. Exercise training in patients with chronic heart failure and atrial fibrillation. J Am Coll Cardiol. 2017;69:1683–91.
  491. Wahlstrom M, Rydell Karlsson M, Medin J et al. Effects of yoga in patients with paroxysmal atrial fibrillation – a randomized controlled study. Eur J Cardiovasc Nurs. 2017;16:57–63.
  492. Skielboe AK, Bandholm TQ, Hakmann S et al. Cardiovascular exercise and burden of arrhythmia in patients with atrial fibrillation – A randomized controlled trial. PLoS One. 2017;12:e0170060.
  493. Lowres N, Neubeck L, Freedman SB et al. Lifestyle risk reduction interventions in atrial fibrillation: a systematic review. European Journal of Preventive Cardiology. 2011;19:1091–100.
  494. Jeroen M.L., Hendriks Rianne de Wit, Harry J.G.M. et al. Nurse-led care vs. usual care for patients with atrial fibrillation: results of a randomized trial of integrated chronic care vs. routine clinical care in ambulatory patients with atrial fibrillation European Heart Journal. 2012;33:2692–2699.
  495. Peterson ED, Ho PM, Barton M et al. ACC/AHA/AACVPR/AAFP/ANA Conceptsfor Clinician-Patient Shared Accountability in Performance Measures: A Report of the American College of Cardiology/American Heart Association Task Force on Performance Measures. Circulation. 2014;130:1984–1994.
  496. Stewart S, Ball J, Horowitz JD et al. Standard versus atrial fibrillation-specific management strategy (SAFETY) to reduce recurrent admission and prolong survival: pragmatic, multicentre, randomised controlled trial. Lancet. 2015;385:775–84.
  497. An J, Niu F, Zheng C et al. Warfarin Management and Outcomes in Patients with Nonvalvular Atrial Fibrillation Within an Integrated Health Care System. J Manag Care Spec Pharm. 2017;23:700–712.
  498. Baker WL1, Cios DA, Sander SD, Coleman CI. Meta-analysis to assess the quality of warfarin control in atrial fibrillation patients in the United States. J Manag Care Pharm. 2009;15:244–52.
  499. Fihn SD, McDonell MB, Vermes D et al. National Consortium of Anticoagulation Clinics . A computerized intervention to improve timing of outpatient follow-up: a multicentre randomized trial in patients treated with warfarin. J Gen Intern Med. 1994;9:131–139.
  500. Rose AJ, Ozonoff A, Henault LE, Hylek EM. Warfarin for atrial fibrillation in community-based practise. J Thromb Haemost .2008; 6:1647–1654.
  501. Liu S, Singer A, McAlister FA et al. Quality of warfarin management in primary care: Determining the stability of international normalized ratios using a nationally representative prospective cohort. Can Fam Physician. 2019;65:416–425.
  502. Roldan V, Marin F, Fernandez H et al. Renal impairment in a «real-life» cohort of anticoagulated patients with atrial fibrillation (implications for thromboembolism and bleeding). Am J Cardiol. 2013;111:1159–1164.
  503. Hohnloser SH, Crijns H, Jvan Eickels M et al. Effect of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med. 2009;360:668–678.
  504. Connolly SJ, Camm AJ, Halperin JL et al. Dronedarone in high-risk permanent atrial fibrillation. N Engl J Med. 2011;365:2268–2276.
  505. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med. 1989;321:406–412.
  506. Wagner EH, Austin BT, Von Korff M. Organizing care for patients with chronic illness. Milbank Q 1996;74:511 – 544., Nuno R, Coleman K, Bengoa R, Sauto R. Integrated care for chronic conditions: the contribution of the ICCC Framework. Health Policy 2012;105:55 – 64.
  507. Du X, Ninomiya T, de Galan B, Abadir E, Chalmers J, Pillai A, Woodward M, Cooper M, Har-rap S, Hamet P, Poulter N, Lip GY, Patel A. Risks of cardiovas-cular events and effects of rou-tine blood pressure lowering among patients with type 2 dia-betes and atrial fibrillation: re-sults of the ADVANCE study. Eur Heart J 2009;30: 1128–1135
  508. Huxley RR, Misialek JR, Agarwal SK, Loehr LR, Soliman EZ, Chen LY, Alonso A. Physi-cal activity, obesity, weight change, and risk of atrial fibrilla-tion: the Atherosclerosis Risk in Communities study. Circ Ar-rhythm Electrophysiol 2014;7:620–625.
  509. Serruys P., Onuma Y., Garg S., et al. Assessment of the SYNTAX score in the Syntax study. EuroIntervention. 2009;5(1):50-56. Электронный калькулятор доступен на сайте http://www.rnoik.ru/files/syntax/
  510. Ducrocq G. et. al. Risk score to predict serious bleeding in stable outpatients with or at risk of atherothrombosis. European Heart J. 2010; 31(10): 1257-1265
  511. Giugliano RP, Ruff CT, Braunwald E et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369:2093–2104.
  512. Clarkesmith DE, Pattison HM, Lip GY, Lane DA. Educational intervention improves anticoagulation control in atrial fibrillation patients: the TREAT randomised trial. PLoS One. 2013;8:e74037.
  513. Aliot E, Breithardt G, Brugada J et al. Atrial Fibrillation AWareness and Risk Education group [comprising the Atrial Fibrillation Association (AFA), the European Heart Rhythm Association (EHRA), Stroke Alliance for Europe (SAFE), and the World Heart Federation (WHF)]. An international survey of physician and patient understanding, perception, and attitudes to atrial fibrillation and its contribution to cardiovascular disease morbidity and mortality. Europace. 2010;12:626–633.
  514. Ziad Hijazi et al ARISTOTLE and RE-LY Investigators The Novel Biomarker-Based ABC (Age, Biomarkers, Clinical History)-Bleeding Risk Score for Patients With Atrial Fibrillation: A Derivation and Validation Study Lancet. 2016 Jun 4;387(10035):2302-2311. doi: 10.1016/S0140-6736(16)00741-8. Epub 2016 Apr 4
  515. Brian F.Gage MD et al Clinical classification schemes for predicting hemorrhage: Results from the National Registry of Atrial Fibrillation (NRAF) Am Heart J . 2006 Mar;151(3):713-9. doi: 10.1016/j.ahj.2005.04.017.
  516. Margaret C Fang et al A New Risk Scheme to Predict Warfarin-Associated Hemorrhage: The ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study. J Am Coll Cardiol 2011 Jul 19;58(4):395-401. doi: 10.1016/j.jacc.2011.03.031.
  517. Emily C O"Brien et al The ORBIT Bleeding Score: A Simple Bedside Score to Assess Bleeding Risk in Atrial Fibrillation Eur Heart J. 2015 Dec 7;36(46):3258-64. doi: 10.1093/eurheartj/ehv476. Epub 2015 Sep 29.
  518. Terzano C, Romani S, Conti V et all. Atrial fibrillation in the acute, hypercapnic exacerbations of COPD. Eur Rev Med Pharmacol Sci. 2014;18(19):2908-2917.
  519. Kato, M., Ogano, M., Mori, Y., Kochi, K., Morimoto, D., Kito, K., … Tanabe, J. (2019). Exercise-based cardiac rehabilitation for patients with catheter ablation for persistent atrial fibrillation: A randomized controlled clinical trial. European Journal of Preventive Cardiology, 26(18), 1931– 1940.

Для продолжения работы требуется Registration
На предыдущую страницу

Предыдущая страница

Следующая страница

На следующую страницу
Список литературы
На предыдущую главу Предыдущая глава
оглавление
Следующая глава На следующую главу

Table of contents

Данный блок поддерживает скрол*